

**CURRICULUM VITAE**  
**Beth Young Karlan, MD**

Office Address

David Geffen School of Medicine at UCLA  
650 Charles E. Young Drive S, 27-117 CHS  
Los Angeles, California 90095

Phone

Phone: (310) 794-3639

Fax

Fax: (424) 529-6277

E-Mail

Bkarlan@mednet.ucla.edu

Place of Birth

New York, NY

Citizenship

USA

**Education**

Harvard-Radcliffe College	B.A.	1978	Biochemical Sciences Magna Cum Laude
Harvard Medical School and Harvard-M.I.T. Program in Health Sciences and Technology	M.D.	1982	Doctor of Medicine
Yale-New Haven Hospital	Residency	1986	Obstetrics and Gynecology
Yale University School of Medicine	Postdoctoral Research Fellowship	1987	Molecular Biology
UCLA School of Medicine	Clinical Fellowship	1989	Gynecologic Oncology
Harvard School of Public Health	Leadership Development for Physicians in Academic Medicine	2008	

**Licensure**

California

#G57519

1986

**Board Certification and Recertification**

American Board of Obstetrics and Gynecology (ABOG)  
ABOG, Division of Gynecologic Oncology

1990, 1998, 2010-present  
1991, 1998, 2010-present

**Academic and Professional Appointments**

**David Geffen School of Medicine at UCLA (formerly UCLA School of Medicine)**  
**Department of Obstetrics and Gynecology**

Assistant Professor, Department of Obstetrics & Gynecology  
Associate Professor, Department of Obstetrics & Gynecology  
Professor, Department of Obstetrics & Gynecology  
Vice Chair, Women's Health Research  
Director, Cancer Population Genetics

1989-1995  
1995-2001  
2001-present  
2019-present  
2019-present

**Cedars-Sinai Medical Center, Department of Obstetrics & Gynecology**

Director, Gynecologic Oncology Research	1990-1995
Director, The Gilda Radner Cancer Program	1991-2018
Director, Division of Gynecologic Oncology	1995-2018
Director, Gynecologic Oncology Fellowship Program Cedars-Sinai Medical Center/UCLA	1998-2005
Director, Women's Cancer Research Institute	2002-2010
Co-Director, Women's Reproductive Cancers, Center of Excellence	2007-2012
Professor, Department of Obstetrics & Gynecology	2009-2018
Director, Women's Cancer Program	2010-2018

**Extramural Professional Activities****National Cancer Advisory Board (NCAB)****2012-present**

Society of Gynecologic Oncology Liaison to the NCAB	2012-present
Communications Subcommittee	2013-2016
Global Cancer Research Subcommittee	2013-present
Cancer Centers Subcommittee	2016-present
Clinical Investigations Subcommittee	2016-present
Experimental Therapeutics Subcommittee	2016-present
Population Science, Epidemiology, and Disparities Subcommittee	2017-present

**National Academy of Medicine (formerly Institutes of Medicine)****2015-present**

Member, Planning Committee of the NAM Interest Group on Maternal & Child Health & Human Development	2018
Member, Steering Committee for National Cancer Policy Forum Workshop on Health Literacy	2018-2019

**Institutes of Medicine (IOM) Committee**

State of the Science in Ovarian Cancer Research Committee	2015-2017
---	-----------

**National Cancer Institute (NCI)**

Investigational Strategies for Detection and Intervention in Early Ovarian Cancer, Organizing Committee	1992
Special Emphasis Panel, Vanguard Clinical Centers for the Women's Health Initiative	1992
Colloquium on "The Costs of Ovarian Cancer Screening"	1992
Consultant, Prostate, Lung, Colon and Ovary Cancer Screening Trial	1992
Consensus Development Conference, Ovarian Cancer: Screening, Treatment, and Follow-up	1994
Group Leader, Strategic Planning Conference on Ovarian Cancer Treatment; New Directions in Ovarian Cancer Research	1997-1998
Reviewer and Site Visitor, Ovarian Cancer Program Project Grant (P01)	2000
Breakout Group Co-Chair Early Detection Screening and Prevention, Ovarian Cancers Progress Review	2001
Co-Chair, Translation Research Section, State of the Science Meeting on Ovarian Cancer	2005
Special Emphasis Panel (SEP) Study Section on New Technology	2007
Reviewer, American Recovery & Reinvestment Act of 2009 (ARRA)	2009
Stakeholders' Meeting on Research Priorities	2010

**Department of Defense (DOD), Ovarian Cancer Research Program**

Integration Panel Member	1999-2003
Executive Committee	2000-2003
Chair, Integration Panel	2002-2003

## **Congressional Testimony**

House Subcommittee on Criminal Justice, Drug Policy and Human Resources: Support for passage of the "Gynecologic Cancer Education and Awareness Act of 2005" (signed into law by President George W. Bush)	2005
House Defense Appropriations Subcommittee: Support for the Department of Defense's "Congressionally Directed Medical Research Program in Ovarian Cancer"	2007

## **Department of Health & Human Services, Food & Drug Administration (DHHS)**

Consultant, Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health	1997-2000
---	-----------

## **Centers for Disease Control (CDC)**

Consultant, National Gynecologic Cancer Campaign " <i>Inside Knowledge</i> "	2009-2010
Consultant, National Gynecologic Cancer Campaign " <i>Inside Knowledge</i> " including Expert Consultant, Health Care Provider Gynecologic Cancer Education Module	2013-present

## **Department of Health Services - State of California**

Cancer Research Council	2001-2005
-------------------------	-----------

## **American Cancer Society**

2018 Research Award Nomination Committee	2018
--	------

## **Professional Society Activities**

### **Society of Gynecologic Oncologists (SGO)**

Program Committee	1994
Postgraduate Course Coordinator	1994
Communications Committee	1994-1998
Government Relations Committee	1995-1998
Program Committee	1997
Informatics Committee	1998-2001
Chairman, Program Committee	1999
President's Task Force	1999-2000
Clinical Data Network Task Force	1999-2002
Board of Directors/Council	1999-2007
ASCO/SGO Liaison Task Force	2003-2008
Government Relations Committee	2003-2013
President-Elect II	2003
President-Elect I	2004

### ***President***

Nominating Committee	2005-2006
Co-Chair, Government Relations Committee	2007-2008
Honor and Awards Committee	2007-2008
Communications Committee	2012-2015
Communications Committee	2013-2015

### **American Board of Obstetrics + Gynecology (ABOG)**

General Oral Exam Examiner	1995-2001
Subspecialty Oral Exam Examiner, Gynecologic Oncology	1997-2015
Subspecialty Division Member, Gynecologic Oncology	2001-2008

### **American College of Obstetricians and Gynecologists (ACOG)**

Presidential Initiative Task Force	2019-
2020	

<b>American College of Surgeons (ACoS)</b>	
Board of Governors	1999-2005
Advisory Council for Gynecology and Obstetrics	1999-2005
<b>American Society of Clinical Oncology (ASCO)</b>	
Cancer Communication Committee	2006-2009
Cancer Education Committee	2007-2010
Government Relations Committee	2009-2012
<b>American Association for Cancer Research (AACR)</b>	
Clinical and Translational Task Force	2009-2010
Surgical Oncology Task Force	2013
<b>American Gynecological and Obstetrical Society (AGOS)</b>	
Nominating Committee	1999
American College of Surgeons Representative	1999-2005
Council	2003-2005
Nominating Committee	2005
Fellowship Committee	
	2007-present
<b>Society for Gynecologic Investigation (SGI)</b>	
Publications Committee	2000
<b>Western Association of Gynecologic Oncologists (WAGO)</b>	
Program Committee	1993
Program Committee	1995
Secretary/Treasurer	1996-2001
President Elect and Program Committee Chair	2002-2003
<b>President</b>	2004
Nominating Committee	2005-2007
<b>Gynecologic Oncology Group (GOG)</b>	
Affiliate Senior Investigator	1990-present
Tumor Biology and Applied Science Committee	1991-1998
Developmental Therapeutics Committee	1995-2002
Cancer Prevention and Control Committee	1996-2002
Co-Principal Investigator, UCLA Institutional Grant	1997-2004
<b>Los Angeles Obstetrical and Gynecological Society</b>	
Council	1997-2004
Program Chair	1999-2000
Secretary/Treasurer	2000-2001
Vice President	2001-2002
<b>President</b>	2002-2003
<b>Cancer Support Community Los Angeles</b>	2018-2020
Professional Advisory Board Member	

## Foundation Activities

### **Foundation for Women's Cancer (formerly Gynecologic Cancer Foundation, [GCF])**

Membership Committee	1992-1995
Communications Committee	1994-2002
Board of Directors, Executive Committee	1996-2002
Chair, Communications Committee	1996-2002
Women's Cancer Network Committee	1999-2006
Chair, Advisory Committee	2002-2008
Development Committee	2011-2016

### **The Clarity Foundation**

Chair, Scientific Advisory Board	2008-present
----------------------------------	--------------

### **Ovarian Cancer National Alliance (OCNA)**

Scientific and Medical Advisory Committee	2000-2016
---	-----------

### **Ovarian Cancer Research Fund Alliance (OCRFA)**

Board of Directors	2009-present
--------------------	--------------

### **Conquer Cancer Foundation (CCF)**

Board of Directors	2012-2015
--------------------	-----------

### **Canary Foundation**

High Grade Serous Cancer Initiative	2019
-------------------------------------	------

## Corporate Board Activities

### **IRIS International, Incorporated**

Board of Directors	2009-2012
Nominating and Governance Committee	2009-2012

### **Invitae Corporation**

Advisory Board	2017-2018
----------------	-----------

## Academic and Institutional Service

### **Cedars-Sinai Medical Center**

Research Institute Advisory Committee	1989-1991
Professional Benefits Committee	1989-1991
Medical Education Committee and Subcommittee on Resident Education	1989-1991
Operating Room Advisory Committee	1990-1994
Professional Appointments Committee	1991-1992
SICU Joint Practice Committee	1991-1992
Pharmacy Subcommittee	1991-1992
Research Committee of the Board	1991-1995
Research Institute Advisory Subcommittees	1991-1996
Obstetrics and Gynecology Resident Advisory Committee	1991-2008
Radiation Oncology Committee	1992-2002
Cancer Committee	1995-1998
OB/Gyn Performance Improvement Committee (PIC)	1995-2002
Cancer Committee (Vice Chair – 2008-2010)	2001-2010
<b>Board of Directors</b>	2006-2012

Community Benefit Committee	2006-2008
Vice-Chair, Medical Policy Committee	2006-2012
Pioneer in Medicine Selection Committee	2006-2012
Academic Promotions and Appointment Council	2007-2011
Advanced BioBank (CSAB) Tissue Repository Research Core Committee	2010-2012
Clinical Resources Committee	2010-2012
Thesis Committee for PhD Student – Maricel Gozo	2010-2013
Steering Committee, Clinical Scholars Program	2010-2016
Cancer Committee	2010-2019
Chair, Cancer Quality Committee	2012-2013
Chair, Cancer Committee	2012-2014
SOCCI Protocol Prioritization Committee (PPC)	2012-2014
Clinical Improvement Committee	2012-2014
High Cost of Drugs Committee	2013-2015
CS Medicine End of Life Group	2012-2015
Cancer Quality Committee	2013-2019
Cancer Grant Workshop Committee	2013-2019
SOCCI CCSG Executive Committee	2013-2019
SOCCI Clinical Program Leaders Committee	2013-2019
SOCCI Senior Leadership Committee	2013-2019
End of Life Care Project, Team Leader for the Quality Council	2015-2019

### **David Geffen School of Medicine at UCLA (formerly UCLA School of Medicine)**

UCLA Curriculum Working Group on Cancer	1990-1992
Scientific Advisor, Revlon/UCLA Women's Cancer Research Program	1990-2005
UCLA Cancer Research Development Program, Mentor/Advisory Committee, NIH (1 K12 CA 01714-01), PI: Dennis Slamon	1991-1998
Jonsson Comprehensive Cancer Center	1991-2005
Co-Director, Breast and Women's Program Area, Jonsson Comprehensive Cancer Center	1996-2005
Director, Gynecologic Oncology Fellowship Program Cedars-Sinai Medical Center/UCLA	1998-2005
CTSI Crest Committee	2016-Present
CTSI KL2 Grant Review Committee	2016-Present
Dossier Review, Academic Personnel Committee	2017

### **Harvard Medical School**

Council, Vice-President	2010-2013
30 <sup>th</sup> Reunion Gift Committee	2011-2012
Chair, Alumni Fund Committee	2011-2015

### **Harvard University**

Board of Overseers	2015-2021
Standing Committees: Natural and Applied Sciences; Schools, the College, and Continuing Education and Alumni Affairs and Development.	
Visiting Committees: Harvard Medical School, Harvard Chan School of Public Health	

### **Other Professional Society Memberships**

American Association for the Advancement of Science	1985-present
American Medical Association	1988-present
American Medical Women's Association	1990-present
American College of Obstetrics and Gynecologists	1991-present
American Association for Cancer Research	1991-present

American Society for Clinical Oncology	1991-present
Association of Women Surgeons	1991-present
Western Association of Gynecologic Oncologists	1991-present
Society of Gynecologic Oncologists	1992-present
Foundation for Women's Cancer (formerly Gynecologic Cancer Foundation)	1992-present
American College of Surgeons	1992-present
American Society for Investigative Pathology, Honorary Member	1994
Society for Gynecologic Investigation	1994-2009
International Gynecologic Cancer Society	1995-present
American Gynecological and Obstetrical Society	1999-present
Society of Pelvic Surgeons	2003-2009
American Gynecological Club	2011-present

### Editorial Services

<b>Editor-in-Chief</b> , <i>Gynecologic Oncology</i>	2008-present
<b>Editor-in-Chief</b> , <i>Gynecologic Oncology Reports</i>	2010-present

### **Editorial Boards**

<i>Gynecologic Oncology</i>	through 2007
<i>Journal of Clinical Oncology</i>	through 2007
<i>Journal of Women's Health</i>	through 1999
<i>International Journal of Molecular Biology</i>	through 2000
<i>Nature Clinical Practice Oncology</i>	through 2007
<i>Obstetrics and Gynecology</i>	through 2007

### **Ad Hoc Reviewer**

<i>Cancer</i>	2000-Present
<i>Cancer Epidemiology and Biomarkers and Prevention</i>	2000-Present
<i>Cancer Research</i>	2000-Present
<i>Clinical Cancer Research</i>	2000-Present
<i>Gynecologic Oncology</i>	2000-Present
<i>International Journal of Gynecological Cancer</i>	2000-Present
<i>Journal of Clinical Oncology</i>	2000-Present
<i>Nature</i>	2000-Present
<i>Nature Clinical Practice Oncology</i>	2000-Present
<i>New England Journal of Medicine</i>	2000-Present
<i>Obstetrics and Gynecology</i>	2000-Present
<i>Oncogene</i>	2000-Present
<i>PLoS</i>	2000-Present
<i>Proceedings of the National Academy of Sciences, U.S.A.</i>	2000-Present

### Honors

ACOG-Ortho Academic Training Fellowship in Obstetrics and Gynecology	1986
James Hudson Brown/Alexander B. Coxe Fellowship, Yale University School of Medicine	1986
Meehan-Miller Award, Yale University School of Medicine	1986
J. G. Moore Award, Western Association of Gynecologic Oncologists	1988
American Cancer Society Clinical Oncology Career Development Award	1990
Berlex Foundation Scholar Award	1992
Richard F. Dwyer-Eleanor W. Dwyer Award for Excellence, Jonsson Comprehensive Cancer Center, UCLA School of Medicine	1993
James F. Nolan Award, Western Association of Gynecologic Oncologists	1993
<b><i>Board of Governors' Endowed Chair in Gynecologic Oncology, Cedars-Sinai Medical Center</i></b>	1995

Award for Excellence, Israel Cancer Research Fund	1996
Nat King Cole Research Award, Research for Women's Cancers	1998
Mother of the Year, Helping Hand of Los Angeles	1998
Women of Distinction, Hadassah, Western Region	1998
Public Service Award, Gynecologic Cancer Foundation	2001
America's Top Doctors for Cancer, Castle Connelly	2005-present
<b>Early Detection Professorship, American Cancer Society</b>	2006-2011
Margaret Greenfield/Carmel Cohen, M.D. Prize for Excellence in Ovarian Cancer Research Gynecologic Cancer Foundation	2008
<b>Clinical Research Professorship, American Cancer Society</b>	2011-2017
"Game Changers 2012, Women Who Impact LA," <i>Los Angeles Magazine</i>	2012
<b>Distinguished Service Award, Society of Gynecologic Oncology</b>	2015
Claudia Cohen Prize for Outstanding Gynecologic Researcher, Foundation for Women's Cancer	2015
<b>Rosalind Franklin Excellence in Ovarian Cancer Research Award, Ovarian Cancer National Alliance</b>	2015
<b>Pioneer in Medicine Award, Cedars-Sinai Medical Center</b>	2016
Triumph Award, American Cancer Society	2016
<b>Fellow of the American Society of Clinical Oncology (FASCO)</b>	2018
<b>Director's Service Award, National Cancer Institute</b>	2018
2019 Southern California Super Doctors, Los Angeles Times	2019
<i>Gynecologic Oncology: Clinical Practice and Surgical Atlas</i> named Core Title in Obstetrics & Gynecology, Doody Enterprises Core Titles in the Health Sciences	2019
Lifetime Achievement Award, Marquis Who's Who	2019
Recipient, Giant of Cancer Care in Gynecologic Malignancies, presented by OncLive	2019

### US and International Patents

PCT/US2013065537 Molecular Signatures of Ovarian Cancer, 1/6/16  
PCT/US2014016562 Ovarian Cancer Vaccines and Vaccination Methods, 2/10/15  
PCT/US2018/024198 Methods and Compositions for Production of Fallopian Tube Epithelium, Pending, 3/23/18

### Research Grants – Active

Granting Agency	Role	Project Title	Project Dates	Total Direct Costs	% Effort
Feldman Foundation	PI	Ovarian Cancer Research Fund	06/01/18 – 05/31/19	\$250,000	5%
Mellen Foundation	PI	BRCA Founder Outreach Study	10/01/17 – 09/30/18	\$50,000	5%
Department of Defense	Co-I	Immune Infiltrate Dynamics in Cancer Progression	05/01/2017 – 04/30/2020	\$153,783	2%
National Institutes of Health/Leidos	PI	Clinical Proteomic Technology Assessment for Cancer	10/12/2016 – 09/30/2017	\$65,949	1%
National Cancer Institute	Co-I	Cancer-Associated Fibroblasts Alter the Composition of $\beta$ Cells in Solid Malignancies	09/02/2016 – 07/31/2021	\$228,750	2.5%
Department of Defense	Co-I	Identifying Therapeutics for Platinum-Resistant Ovarian Cancer by Next Generation Mechanotyping	08/15/2016 – 08/14/2017	\$38,326	1%
Department of Defense	Co-I	Untapped Therapeutic Targets in the Tumor Microenvironment	08/01/2016 – 07/31/2019	\$147,783	1%
Ovarian Cancer Research Fund	PI	Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma	01/01/2016 – 12/31/2018	\$818,181	10%
University of Massachusetts/National	PI	Continuation of Follow-Up of DES-Exposed Cohorts	09/22/2015 – 09/21/2020	\$16,163	1%



Institutes of Health					
----------------------	--	--	--	--	--

**Therapeutic Clinical Trials – Active**

<b>Trial Sponsor</b>	<b>Role</b>	<b>Clinical Trial</b>	<b>Trial Dates</b>	<b>Total Direct Costs</b>	<b>% Effort</b>
Pfizer, <i>B9991010</i>	Co-I	A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate Efficacy & Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer	02/15/2017 – 02/14/2020	\$15,480	1%
AstraZeneca, <i>D8488C00001</i>	Co-I	Study to Assess Efficacy & Safety of Cediranib & Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer who do not Carry a Deleterious Germline <i>BRCA</i> Mutation	02/01/2017 – 01/31/2020	\$15,480	1%
Merck Sharp & Dohme	Co-I	A Phase II Study of Pembrolizumab with Cisplatin and Gemcitabine Treatment in Patients with Recurrent Platinum-Resistant Ovarian Cancer	12/02/2015 – 12/01/2018	\$221,805	1%
Tesaro, Inc	Co-I	Phase 2, Open Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Women with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received At least Three Previous Chemotherapy Regimens	09/15/2015 – 09/14/2018	\$131,444	1%
AstraZeneca, <i>GOG-3004</i>	Co-I	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with <i>BRCA</i> Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy	09/22/2014 – 09/21/2017	\$47,949	1%
Tesaro, Inc	Co-I	Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer	11/08/2013 – 11/07/2015	\$182,715	1%

**Research Grants – Completed**

<b>Funding Agency</b>	<b>Role</b>	<b>Project Title</b>	<b>Project Dates</b>	<b>Total Direct Costs</b>	<b>% Effort</b>
American Cancer Society	PI	Biomarkers for Ovarian Cancer Early Detection, Prognostication and Therapy	07/01/2011 – 06/30/2017	\$105,000	10%
National Cancer Institute, (PQA3)	Co-I	Why is Ovarian Cancer Primarily a Disease of Postmenopausal Women	05/01/2015 – 04/30/2017	\$130,500	5%

Hearing the Ovarian Cancer Whisper (H.O.W.)	Co-I	Modeling Fallopian Tube Epithelium with Induced Pluripotent Stem Cells: A Novel Method for the Study of Serous Cancinoma Pathogenesis	07/01/2014-06/30/2016	\$50,000	3%
National Institutes of Health/Leidos	PI	Clinical Proteomic Technology Assessment for Cancer	07/01/2013-05/31/2016	\$79,205	1%
Department of Defense	Co-I	Tumor Microenvironment Gene Signature as a Prognostic Classifier and Therapeutic Target	05/05/2014 – 05/04/2016	\$125,000	4%
Moodie Foundation	PI	Pluripotent Stem Cells and Stromal Signatures	07/01/2014 – 12/31/2015	\$206,265	5%
Avon	Co-I	Large Oncosomes in Tumor Tissues and in the Circulation of Patients with Aggressive Breast Cancer	10/01/2013 – 09/30/2015	\$150,000	1%
Tufts Medical Center/ National Institutes of Health	PI	Continuation of Follow-Up of DES-Exposed Cohorts	09/30/2010 – 09/29/2015	\$19,620	2%
Department of Defense/ MD Anderson Cancer Center	Co-I	Consortium to Study Long-Term Survivors of Ovarian Cancer	08/15/2013 – 08/14/2015	\$225,000	1%
Entertainment Industry Foundation – Revlon Run 2013	PI	The Gilda Radner Hereditary Cancer Program	03/01/2014 – 02/28/2015	\$40,000	1%
National Cancer Institute, HHSN2612010000161	PI	The Cancer Genome Atlas (TCGA) Pilot Program, Endometrial	04/01/2010 – 09/30/2014	\$57,063	1%
Fred Hutchinson Cancer Research Center/ National Cancer Institute, 5 P50 CA083636-12	PI	Pacific Ovarian Cancer Research Consortium - SPORE3 Project 1: Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated Risk Women	07/01/2009 – 06/30/2014	\$16,235	5%
Fred Hutchinson Cancer Research Center/ National Cancer Institute, 5 P50 CA083636-12	PI	Pacific Ovarian Cancer Research Consortium - SPORE 3 Project 4: Clinical Implication of the Acquisition of <i>BRCA1/2</i> Function in <i>BRCA1/2</i> Deficient Ovarian Carcinoma	07/01/2009 – 06/30/2014	\$12,318	5%
Fred Hutchinson Cancer Research Center/ National Cancer Institute, 5 P50 CA083636-12	PI	Pacific Ovarian Cancer Research Consortium - SPORE 3 Core B: Clinical Specimen Management and Characterization Core	07/01/2009 – 06/30/2014	\$17,731	2%
Fred Hutchinson Cancer Research Center/ National Cancer Institute, 5 P50 CA083636-12	PI	Pacific Ovarian Cancer Research Consortium - SPORE 3 Core D: Biostatistics and Data Management Core	07/01/2009 – 06/30/2014	\$4,927	2%
American Cancer Society	Co-I	Defining Key Drivers in Ovarian Carcinogenesis	07/01/2010 – 06/30/2014	\$150,000	2%
Entertainment Industry Foundation – Revlon Run 2012	PI	The Gilda Radner Hereditary Cancer Program	03/01/2013 – 02/28/2014	\$25,000	1%
Stenn Family Foundation	PI	Stress and Quality of Life in <i>BRCA</i> Mutation Carriers	07/01/2008 – 06/30/2013	\$200,000	3%
Entertainment Industry Foundation – Revlon Run 2011	PI	The Gilda Radner Hereditary Cancer Program	03/01/2012 – 02/28/2013	\$25,000	1%
Department of Defense,	Co-I	Role of Cyclin E as an Early Event in Ovarian	04/01/2009 –	\$135,332	5%

W81XWH-089-1-0209		Carcinogenesis	03/31/2012		
Entertainment Industry Foundation – Revlon Run 2010	PI	The Gilda Radner Hereditary Cancer Program	03/01/2011 – 02/29/2012	\$25,000	1%
Dr. Susan Love Research Foundation	PI	Follow-up Study of Breast Health Outcomes and Selected Biomarkers in Women at High Risk for Breast Cancer: The Serial Evaluation of Ductal Epithelium (SEDE) Clinical Trial	03/01/2011 – 02/29/2012	\$6,232	1%
David and Linda Shaheen Foundation	PI	WCRI Biorepository and Relational Database and Chart Review	07/01/2009 – 06/30/2011	\$60,000	1%
American Cancer Society	PI	Identification of Biomarkers for Ovarian Cancer Early Detection and Prognosis	07/01/2006 – 06/30/2011	\$60,000	15%
Memorial Sloan Kettering Institute for Cancer Research/DOD OCRP-IDEA-DL-01 OC093150	PI	Toward Personalized Ovarian Cancer Therapy	04/01/2010 – 03/31/2011	\$35,844	2%
Entertainment Industry Foundation	PI	The Gilda Radner Ovarian Cancer Detection Program	01/01/1994 - 12/31/2010	\$25,000	1%
Tufts Medical Center/ National Institutes of Health	PI	Continuation of Follow-Up of DES-Exposed Cohorts	09/30/2005 – 09/29/2010	\$20,430	1%
National Cancer Institute	PI	Biospecimen Core Repository for the Cancer Genome Atlas	09/01/2008 – 08/31/2010	\$198,197	2.5%
David and Linda Shaheen Foundation	PI	Targeted Outreach for Breast and Gynecologic Cancers and HPV Vaccine at the Los Angeles Sparks Games	07/01/2009 – 06/30/2010	\$18,480	1%
LM Sarcoma Direct Research Foundation	Co-I	A Preclinical Mouse Model for Targeted Therapy in Uterine Leiomyosarcoma	07/01/2009 – 06/30/2010	\$25,000	2%
Liddy Shriver Sarcoma Initiative	Co-I	A Preclinical Mouse Model for Targeted Therapy in Uterine Leiomyosarcoma	07/01/2009 – 06/30/2010	\$25,000	2%
Private	PI	Women’s Cancer Research Institute Research Laboratory	07/01/2006 – 06/30/2010	\$135,226	2%
Department of Defense	PI	Affinity Based Serum Proteomics for Ovarian Cancer	07/01/2005 – 06/30/2010	\$3,487	2%
Callaway Golf Foundation	PI	Ovarian Cancer Early Detection and Biomarker Discovery	04/30/2008 – 04/29/2010	\$141,188	5%
David and Linda Shaheen Foundation	PI	Genetic Counseling for Hereditary Cancer Risk	07/01/2008 – 06/30/2009	\$46,360	1%
David and Linda Shaheen Foundation	PI	Cervical Cancer Vaccine Clinic	07/01/2008 – 06/30/2009	\$45,320	1%
David and Linda Shaheen Foundation	PI	Jackie Green Lecture Series	07/01/2008 – 06/30/2009	\$37,320	1%
David and Linda Shaheen Foundation	PI	Tissue Bank Expansion	07/01/2008 – 06/30/2009	\$56,320	1%
National Institutes of Health/Specialized Program in Research Excellence (SPORE) Ovarian Cancer	PI	SPORE in Ovarian Cancer Pacific Ovarian Cancer Research Consortium: Informatics Core	09/30/2004 – 06/30/2009	\$13,082	5%
National Institutes of Health/Specialized Program in Research Excellence (SPORE) Ovarian Cancer	PI	SPORE in Ovarian Cancer Pacific Ovarian Cancer Research Consortium: Leadership Core	09/30/2004 – 06/30/2009	\$9,383	5%
National Institutes of Health/Specialized Program in Research	PI	SPORE in Ovarian Cancer Pacific Ovarian Cancer Research Consortium: Project 1 Early Detection Biomarker Panel	09/30/2004 – 06/30/2009	\$10,694	5%

Excellence (SPORE) Ovarian Cancer					
National Institutes of Health/Specialized Program in Research Excellence (SPORE) Ovarian Cancer	PI	SPORE in Ovarian Cancer Pacific Ovarian Cancer Research Consortium: Proteomics Remission Monitoring Trial	07/01/2005 – 06/30/2008	\$43,972	2.5%
David and Linda Shaheen Foundation	PI	Expansion of the Women's Cancer Research Institute Tissue Bank	07/01/2003 – 06/30/2008	\$38,446	1%
Smith-Kline Beecham	PI	Glaxo-Smith-Kline Research Fellowship Grant	12/01/2003 – 11/30/2007	\$10,000	1%
Milken Family Foundation	PI	Ovarian Cancer Biomarker Discovery Project	07/01/2004 – 06/30/2007	\$666,667	5%
Department of Defense	PI	Center for Evaluating Biomarkers for Early Detection of Breast Cancer	09/23/2003 – 09/22/2006	\$50,178	1%
National Institutes of Health	Co-I	Cigarette Smoking, HPV and Cervical Neoplasia: A Model Environment - Gene Interactions in Cervical Carcinogens	07/01/2003 – 06/30/2006	\$19,200	1%
Rexall Sundown, Inc	PI	The Gilda Radner Cancer Detection Program	01/01/2005 – 12/31/2005	\$100,000	1%
National Institutes of Health	PI	Continuation of Follow-up of DES-Exposed Cohorts	09/30/2000 – 09/29/2005	\$21,166	1%
David and Linda Shaheen Foundation	PI	Women's Cancer Research Institute Community Outreach Program	07/01/2003 – 06/30/2005	\$17,250	1%
National Institutes of Health/Specialized Program in Research Excellence (SPORE) Ovarian Cancer	PI	Pacific Ovarian Cancer Research Consortium Core 1: Leadership	09/30/1999 – 09/29/2004	\$15,529	5%
National Institutes of Health/Specialized Program in Research Excellence (SPORE) Ovarian Cancer	PI	Pacific Ovarian Cancer Research Consortium Project 4: Methods to Select and Use Biomarker Panels for Screening	09/30/1999 – 09/29/2004	\$11,760	5%
Mosher Family Foundation	PI	Finding an Early Diagnostic Tool for Ovarian Cancer	07/01/2002 – 06/30/2004	\$50,000	1%
Department of Defense	PI	Genetic Definition and Phenotypic Determinants of Human Ovarian Carcinomas	07/01/1999 – 06/30/2002	\$666,667	10%
Ahmanson Foundation	PI	Tumor Suppressor Genes as Targets for Ovarian Cancer Gene Therapy	09/01/1997 - 08/31/1999	\$145,000	5%
Mary Kay Ash Charitable Foundation	PI	Reinstating the Guard: P53 Gene Therapy for Human Ovarian Carcinoma	07/01/1997 – 06/30/1999	\$40,000	2%
Ahmanson Foundation	PI	Identification of a Unique Ovarian Inhibitory Substance	01/01/1997 – 12/31/1997	\$118,500	5%
Gynecologic Cancer Foundation	PI	Characterization of a Novel Ovarian Inhibitory Substance	01/01/1995 – 12/31/1995	\$45,000	2%
Concern Foundation for Cancer Research	PI	Stroma-Epithelial Interaction in Ovarian Carcinogenesis	07/01/1993 - 06/30/1995	\$35,000	1%
Berlex Foundation	PI	The Role of HER-2/neu Oncogene Overexpression in Transformation and Tumorigenesis of Human Ovarian Surface Epithelium	07/01/1992 - 06/30/1993	\$60,000	1%
American Cancer Society	PI	Regulation of HER-2/neu Oncogene Expression in Human Ovarian Epithelial Carcinomas	07/01/1990 - 06/30/1993	\$30,000	1%
Biomedical Research Support Grant	PI	Regulation of HER-2/neu Oncogene Expression	07/01/1990 - 06/30/1991	\$13,372	1%

California Institute of Cancer Research	PI	Regulation of HER-2/neu Oncogene Expression in Human Ovarian Epithelial Carcinomas	07/01/1989 - 06/30/1991	\$14,990	1%
California Institute of Cancer Research	PI	Plasminogen Activator Secretion by Epithelial Ovarian Carcinomas in Short Term Organ Culture: Comparison Between Primary and Metastatic Sites and Clinical Correlations	07/01/1988 - 06/30/1989	\$26,004	1%
James Hudson Brown, Alexander B. Coxe Fellowship, Yale University School of Medicine	PI	Glucocorticoid Inhibition of Plasminogen Activator Cells: Inhibition of Plasminogen Activators, Cell Growth, and Morphological Alterations	07/01/1986 - 06/30/1987	\$14,000	1%
ACOG-Ortho Fellowship in Obstetrics and Gynecology, Yale University School of Medicine	PI	Human Epithelial Ovarian Cancer	07/01/1986 - 06/30/1987	\$25,000	1%

### **Therapeutic Clinical Trials – Completed**

<b>Funding Agency</b>	<b>Role</b>	<b>Project Title</b>	<b>Project Dates</b>	<b>Total Direct Costs</b>	<b>% Effort</b>
AstraZeneca	Co-I	Phase 3 Randomized, Open Label, Randomized, Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy	06/10/2015 – 06/09/2018	\$15,000	1%
Dana-Farber Cancer Center/National Cancer Institute	Co-I	Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer	06/01/2012 – 02/28/2017	\$17,500	1%
Amgen, Inc	PI	A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	01/20/2011 – 10/31/2016	\$127,329	2%
AstraZeneca	PI	Phase II Randomized, Double-Blind, Multicenter Study to Assess the Efficacy of AZD2281 in the Treatment of Patients with Platinum Sensitive Serous Ovarian Cancer Following Treatment with Two or More Platinum Containing Regimens	10/22/2008 – 09/30/2016	\$59,903	2%
Cancer International Research Group (CIRG), TRIO14	PI	A Randomized, Double-Blind, Placebo Controlled, Multi-Center, Phase II Study of Adding AMG 479, A Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) To First Line Chemotherapy in Patients with Optimally Debulked (< 1 cm) Epithelial Ovarian Cancer	08/01/2009 – 05/01/2015	\$95,011	2%

Novartis Pharmaceuticals	Co-I	A Phase II, Open-Label, Single-Arm, Non-Randomized, Multi-Center Study to Evaluate the Efficacy of Oral TKI258 as Second-Line Therapy in Patients with Either FGFR2 Mutated or Wild-Type Advanced and/or Metastatic Endometrial Cancer	07/12/2011 – 12/31/2014	\$43,374	1%
Astex Pharmaceuticals	Co-I	A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	02/01/2014 – 06/30/2014	\$14,250	1%
Astra Zeneca	PI	A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and Tolerability of Oral Olaparib in Combination with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients with Platinum Sensitive Advanced Serous Ovarian Cancer	04/22/2010 – 02/28/2014	\$41,851	2%
Amgen, Inc	PI	A Randomized Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination with AMG 386 in Subjects with Advanced Recurrent Ovarian Cancer	08/01/2007 – 07/31/2013	\$142,372	1%
Cancer International Research Group (CIRG), TRIO15	PI	A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, A Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients with Recurrent Platinum-Sensitive Ovarian Cancer	07/01/2009 – 07/31/2013	\$35,408	2%
Genentech, Inc	PI	A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma	04/01/2007 – 03/31/2013	\$110,885	1%
Abbott Laboratories	PI	A Phase 2 Randomized Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer	03/15/2010 – 01/31/2013	\$104,109	2%
Astra Zeneca	PI	A Phase II, Open Label, Randomized, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Three Different Doses of AZD2281 Given Orally Once or Twice Daily and Intravenous Liposomal Doxorubicin Given Monthly in Patients with Advanced <i>BRCA1</i> - or <i>BRCA2</i> -Associated Ovarian Cancer Who Have Failed Previous Platinum-Based Chemotherapy	04/30/2008 – 02/29/2012	\$15,249	1%
Menarini Ricerche S.P.A.	Co-I	A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients with Epithelial Ovarian Cancer after Complete Response to First-line Chemotherapy-Protocol No. ABA-1	05/25/2007 – 01/31/2012	\$78,279	2%

Genentech	PI	A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of GDC-0449 Maintenance Therapy in Patients with Ovarian Cancer in a Second or Third Complete Remission	10/01/2008 – 02/15/2011	\$35,376	2%
Bristol-Myers Squibb	PI	A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy	10/12/2009 – 09/30/2010	\$10,000	2%
MEI (Marshall Edwards Pty Limited)	PI	Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-Resistant or Platinum-Refractory Late Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following At least Second Line Platinum Therapy	09/02/2007 – 02/01/2010	\$9,500	2%
Cytec Health Corporation	PI	Serial Evaluation of Ductal Epithelium (SEDE) and Breast Health Outcomes in Women at High Risk for Breast Cancer	11/21/2003 – 11/20/2009	\$573,681	2%
Correlogic Systems, Inc	PI	Serum Proteomics: For Detection of Ovarian Cancer Using the Correlogic Systems, Inc. Serum Pattern Blood Test System	12/06/2006 – 12/05/2008	\$6,424	2%
Genentech	PI	A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Pertuzumab (rhuMAb 2C4) in Combination with Gemcitabine and the Effect of Tumor-Based HER2 Activation in Subjects with Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	04/01/2005 – 12/31/2007	\$3,750	2%
Unither Pharmaceuticals	PI	A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin	04/01/2003 – 12/31/2007	\$80,043	2%
Aventis Pharmaceuticals	PI	A Phase II Evaluation of Capcitabine and Docetaxel in Recurrent Ovarian, Peritoneal, and Fallopian Tube Carcinoma	11/01/2002 – 04/01/2007	\$55,832	2%
Genentech	PI	A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor Based HER2 Activation on The Efficacy of RHUMaB 2C4 (PERTuzumab) In Subjects with Advanced, Refractory or Recurrent Ovarian Cancer	07/01/2003 – 12/31/2006	\$479,484	2%
Eli Lilly & Co	PI	Randomized Phase III Trial of Gemzar versus Doxil with Crossover Treatment Option for Patients with Platinum-Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third Line Chemotherapy	09/01/2002 – 08/31/2004	\$11,250	2%
Marion Merrell Dow, Inc	PI	A Four Arm Double-Blind Randomized Dose Response Study of Oral Dolasetron Mesylate in Patients Receiving Carboplatin Containing Chemotherapy	07/01/1993 – 06/30/2004	\$117,000	2%
Novartis	PI	Study of PSC 833 w/ PC-PSC vs. PC in Ovarian or Primary Cancer of Peritoneum	08/01/1998 – 08/15/2002	\$10,086	2%

Smith-Kline Beecham	PI	A Phase II Trial of Topotecan in Patients with Platinum Sensitive Ovarian Cancer	11/10/1998 – 03/31/2000	\$3,200	2%
---------------------	----	--	-------------------------	---------	----

### **Selected Invited Lectureships - Since 2012**

1. “Personalized Approaches to Ovarian Cancer,” UCSD, Department of Reproductive Medicine Grand Rounds, La Jolla, CA, January 25, 2012
2. “What is the Origin of Serous Ovarian Carcinoma: Surface Epithelium vs. Distal Fallopian Tube,” Scientific Session at American Association for Cancer Research Annual Meeting, Chicago, IL, April 01, 2012
3. “Individualized Approaches to Ovarian Cancer,” MD Anderson Cancer Center, Houston, TX, July 13, 2012
4. “Personalized Approaches to Ovarian Carcinoma,” Fifteenth Annual West Hawaii Cancer Symposium, Kailua-Kona, HI, September 07, 2012
5. “Inherited Susceptibility to Ovarian Cancer: Clinical Implications and Challenges,” Grand Rounds, Albert Einstein School of Medicine, New York, NY, October 09, 2012
6. “Personalized Approaches to Ovarian Cancer,” New York Obstetrical Society, New York, NY, October 09, 2012
7. “Individualized Approaches to Ovarian Cancer,” New Avenues in Oncology – The Road to Personalized Medicine, Post-graduate course, Cedars-Sinai Medical Center, Los Angeles, CA, October 26-27, 2012
8. “Scientific Integrity and Publication Ethics,” Cedars-Sinai Medical Center, Clinical Scholars Program, Los Angeles, CA, December 19, 2012
9. “The Mechanics of Manuscript Preparation: Lessons from the Editor-in Chief of *Gynecologic Oncology*,” 44<sup>th</sup> Annual Meeting on Women’s Cancer, Society of Gynecologic Oncology, Los Angeles, CA, March 08, 2013
10. “What is the Best Strategy to Reduce Ovarian Cancer Mortality?,” Canary Foundation Early Detection Symposium, Stanford, CA, October 15, 2013
11. Visiting Professor, “Translational Medicine in Gynecologic Oncology,” Peking Union Medical College Hospital, Beijing, China, October 23, 2013
12. Presidential Speaker, “How Can We Publish a Paper in Gynecologic Oncology and Specialists Training of Gynecological Oncology in the USA,” China Society of Gynecologic Oncology, Nanjing, China, October 26, 2013
13. Visiting Professor, “Translational Medicine in Gynecologic Oncology,” Fudan University Shanghai Cancer Center, Shanghai, China, October 28, 2013
14. Visiting Professor, “What is the Best Strategy to Reduce Ovarian Cancer Mortality?” Cancer Center Lecture, University of Alabama, Birmingham, AL, November 14, 2013
15. Inaugural Lecturer, “The Mechanics of Writing and Publishing Great Papers: Perspective from the Editor-in-Chief of *Gynecologic Oncology*,” Ronald D. Alvarez Lectureship at the University of Alabama, Birmingham, AL, November 15, 2013
16. Visiting Professor, “Pearls and Perils of Manuscript Publishing: Lessons Learned as Editor-in-Chief,”



Radiology Special Lecture Series, Memorial Sloan-Kettering Cancer Center, New York, NY, March 13, 2014

17. Visiting Professor, "What is the Best Strategy to Reduce Ovarian Cancer Mortality?" Gynecology Service Conference, Memorial Sloan-Kettering Cancer Center, New York, NY, March 13, 2014
18. Course Chair, "Introduction of Issues: Controversies Facing Clinicians," Advances in Care for the New Millennium: 20<sup>th</sup> Anniversary *BRCA* Gene Symposium, Los Angeles, CA, September 13, 2014
19. "Molecular Predictor of Residuals in Patients with Ovarian Cancer" and "Neoadjuvant Chemotherapy in Ovarian Cancer – Pro Side," 5<sup>th</sup> Trope-Kolstad Meeting, the Norwegian Radium Hospital, Oslo, Norway, December 05, 2014
20. "Curative Strategies for Primary Disease," HHMT 13<sup>th</sup> International Forum on Ovarian Cancer, Toledo, Spain, January 17-21, 2015
21. "Ovarian Cancer Detection and Prevention," 9<sup>th</sup> Annual Joining FORCEs Against Hereditary Cancer Conference, Philadelphia, PA, June 18-20, 2015
22. "Genomics in Risk Assessment and Tailoring Treatment for Women with Ovarian Cancer," Ovarian Cancer National Alliance Conference, San Diego, CA, July 24-26, 2015
23. "Ovarian Cancer: State of the Art Treatment and Importance of Enrollment in Clinical Trials," Foundation for Women's Cancer, 2015 Ovarian Cancer Survivor's Course, Duarte, CA, September 13, 2015
24. "Managing Your Inheritance: Are Your Genes the Roadmap of your Life?" and "Women are the Stronger Sexx: Can we use Genetics to Control our Destiny?" TIGER 21 2016 Annual Conference, Beverly Hills, CA, February 03-05, 2016
25. "Precision Medicine and Opportunities to Improve Gynecologic Oncology Outcomes," 68<sup>th</sup> Annual Midwinter Radiology and Radiation Oncology Conference & Conjoint Nuclear Medicine Seminar, Pasadena, CA, February 27-28, 2016
26. "New Strategies for Preventing Gynecologic Cancers," Department of OB/Gyn Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA, March 09, 2016
27. "New Strategies for Preventing Gynecologic Cancers," Department of OB/Gyn Grand Rounds, David Geffen School of Medicine at UCLA, Los Angeles, CA, April 22, 2016
28. "Manuscript Preparation, Publication and Peer-Review," Department of OB/GYN Grand Rounds, University of Washington, Seattle, WA, April 19, 2017
29. "Strategies for Preventing Gynecologic Cancer", OB/GYN Visiting Professor Lecture, Winthrop University Hospital, Mineola, N.Y., December 1, 2017
30. "iPSC Technologies Can Improve Ovarian Cancer Outcomes", Regenerative Medicine Institute Retreat, Cedars Sinai Medical Center, Los Angeles, CA, May 18, 2018.
31. "Ask the Experts", Ovarian Cancer Research Fund Alliance, Chicago, IL, July 9, 2018
32. Invited Professor, Red House Forum, China, June 13-15, 2019.

### Other Endowed Lectureships

1. Heskett Lecturer, Northwestern University, Chicago, IL, 2003
2. Ernest Page Lecturer for Residents' Research Day, University of California, San Francisco, CA, 2003
3. Henderson Lectureship, University of Toronto, Ontario, Canada, 2003
4. Shirley Nissen Lectureship, University of California, Irvine, Orange, CA, 2003
5. Richard E. Symmonds Lectureship, Mayo Clinic, Rochester, MN, 2003
6. Viviane Scott Lectureship, Stanford University, Stanford, CA, 2005
7. William E. Studdiford, Jr., Lectureship, New York University, New York, NY, 2005
8. Barbara Moore Jordan Lectureship, Memorial Sloan-Kettering Cancer Center, New York, NY, 2005
9. Samuel A. Cosgrove Memorial Lecture, "Routine Salpingectomy – A Debate," 2015 ACOG Annual Clinical and Scientific Meeting, San Francisco, CA, May 02-06, 2015
10. Marjorie Beth Salmon Lecture, Seminars in Oncology, Dana-Farber Cancer Center, "Strategies for Preventing Gynecologic Cancers", November 14, 2017
11. Keynote Speaker, OncLive National Fellows Forum, "Strategies for Preventing Gynecologic Cancers", April 27, 2018
12. Arthur Herbst Lecturer, Grand Rounds, University of Chicago, "Strategies for Preventing Gynecologic Cancers", May 4, 2018

### Selected Community Lectures – Since 2012

#### **2012**

"Conversations About Cancer," Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA  
Cedars-Sinai Board of Governors Health Care College, Los Angeles, CA  
Cedars-Sinai Legacy Society, Palm Springs, CA

#### **2013**

"My Role as an ACS Funded Clinical Professor and the Importance of Funding Young Investigators," American Cancer Society Event, Los Angeles, CA, May 21, 2013  
American Cancer Society Event, Video Shoot for ACS Campaign, Los Angeles, CA, May 11, 2013  
"Women's Health – Everything but Cancer: Heart, Bowels and More," Cedars-Sinai Board of Governors Health Care College, Los Angeles, CA, May 07, 2013  
"Improving Cancer Outcomes in the Era of Limited Health Care Resources," Beverly Hills Rotary Club, Beverly Hills, CA, May 06, 2013  
"Winning the Next Chapter of our Lives," Trusteeship Conversations Event, Temple Emanuel, Los Angeles, CA, February 23, 2013

#### **2014**

Mission Chair, American Cancer Society 100<sup>th</sup> Birthday Celebration Ball, Beverly Wilshire Hotel, Beverly Hills, CA, May 17, 2014

**2015**

“Who Shall Live and Who Shall Die. . . and Who Decides?” Temple Emanuel of Beverly Hills in Partnership with Cedars-Sinai Medical Center, Los Angeles, CA

**2016**

“Beverly Hills Tomorrow 2021: A Vision of the Future; An Interview with CNN’s Larry King,” City of Beverly Hills and Beverly Hills Chamber of Commerce, Wallis Annenberg Center for the Performing Arts, April 21, 2016

“Conversations About Cancer: *Moonshot Initiative*,” C Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SLS Hotel, Beverly Hills, CA, November 30, 2016

**2017**

“BRCA and You: What’s Jewish About BRCA and How You Can Use it to Prevent Cancer and Save a Life,” Jewish Federation of North America 2017 General Assembly, November 13, 2017

**2018**

“Jewish Wisdom & Wellness: A Festival of Learning - Hear Her, Heal Her: A Jewish Conversation about Women’s Health”, Cedars-Sinai and the HUC-JIR Kalsman Institute on Judaism & Health, April 15, 2018

Hereditary Cancer Risk Symposium: “Arm Yourself with Knowledge”, Sharsheret, Basser Center for BRCA, Cedars-Sinai, Temple Israel of Hollywood and Ovarian Cancer Circle, May 1, 2018

### **Selected Broadcast Media**

CNN <i>Larry King Live</i>	1996
NBC <i>Nightly News</i>	1999, 2001
MSNBC <i>Live</i>	2001
CBS <i>Evening News</i>	2001
NBC <i>Today Show</i>	2001, 2004, 2007
ABC <i>Good Morning America</i>	2001, 2005, 2006
Local Affiliates: ABC, FOX	2006, 2007
KCET	2007
Satellite Media Tour, Gynecologic Cancer Awareness, Gynecologic Cancer Foundation	2007, 2008, 2009
The Group Room, Cancer Talk Radio	2009
PBS Documentary: <i>The Whisper – The Silent Crisis of Ovarian Cancer</i>	2009
Vital Options International – Talk Radio	2011
Hallmark Cable Television Show – Home and Family	2012
Interview for Studio 11 – Fox News	2013
AirTalk Radio with Larry Mantle – <i>HPV Vaccinations</i>	2014
CBS Evening News, various print and television media: Report on the State of the Science on Ovarian Cancer Research, national release from the National Academies of Science, Engineering and Medicine	2016

### **Selected Mentored Fellows in Leadership**

Name	Training Period	Current Position
Jeffrey Fowler, MD	1989-1991	Director, Division of Gynecologic Oncology The Ohio State University Wexner Medical Center
Laila Mudersbach, MD	1989-1991	Chair, Department of Obstetrics and Gynecology Keck Medicine of USC
Robin Farias-Eisner, MD, PhD	1990-1992	Chief, Gynecology and Gynecologic Oncology UCLA Medical Center

Kathryn McGonigle, MD	1991-1993	Clinic Chief, Women's Cancer Care of Seattle, University of Washington/Northwest Hospital, Seattle, WA
Walter Gotlieb, MD, PhD	1992-1994	Director, Surgical Oncology, McGill University Director, Gynecologic-Oncology, Jewish General Hospital
Robert Bristow, MD	1995-1998	Chairman, Department of Obstetrics and Gynecology UC Irvine Medical Center
Lee-may Chen, MD	1996-1999	Director, Division of Gynecologic Oncology UCSF Medical Center
S. Diane Yamada, MD	1996-1999	Chief, Section of Gynecologic Oncology, University of Chicago Medicine, Chicago, IL
Christine Holschneider, MD	1998-2001	Chief, Department of Obstetrics and Gynecology Olive View-UCLA Medical Center
Jing Wang Chiang, MD	2001-2004	Chief, Division of Gynecologic Oncology, Santa Clara Valley Medical Center, San Jose, CA
Oliver Dorigo, MD, PhD	2002-2005	Director, Division of Gynecologic Oncology Stanford University Medical Center

### **Selected Mentored Fellows**

Name	Training Period	Current Position
Catherine Casey, MD	1993-1995	Minnesota Oncology, Edina, Minnesota
Young Bae Kim, MD	1994-1996	Tufts Medical Center, Boston, MA
John Elkas, MD	1997-2000	Mid-Atlantic Gynecology Oncology and Pelvic Surgery Associates, Annandale, VA
Andrew Li, MD	1999-2002	Cedars-Sinai Medical Center, Los Angeles, CA
Sanaz Memarzadeh, MD, PhD	2000-2003	UCLA Medical Center, Los Angeles, CA
Christine Walsh, MD, MS	2002-2005	Cedars-Sinai Medical Center, Los Angeles, CA
Allison Axtell, MD	2003-2006	Kaiser Permanente, Los Angeles, CA
Amer Karam, MD	2003-2006	Stanford Women's Cancer Center, Palo Alto, CA
James Pavelka, MD	2005-2008	Good Samaritan Women's Center, Cincinnati, Ohio
Lejla Delic, MD	2007-2010	Sutter Health, San Francisco, CA
Nicole Fleming, MD	2008-2011	MD Anderson Cancer Center, Houston, TX
Kristine Penner, MD	2009-2012	UC Irvine Medical Center, Irvine, CA
Elena Diaz, MD	2010-2013	Northshore University Health System, Evanston, IL
Joshua Cohen, MD	2011-2014	UCLA Medical Center, Los Angeles, CA
Marie Holzapfel, MD	2012-2015	The Permanente Medical Group, Santa Clara, CA
Mary Tilley Jenkins Vogel, MD	2013-2016	Northshore University Health System, Evanston, IL
Mae Zakhour, MD	2013-2016	Spectrum Health Medical Group, Grand Rapids, MI
Margaret Liang, MD	2014-2017	The University of Alabama at Birmingham
Annie Liu, MD	2015-2018	Kaiser Permanente Orange County, CA
Melissa Hodeib, MD	2015-2018	UCI University Physicians & Surgeons, Orange, CA
Heidi Chang, MD	2016-2019	

**Selected Mentored Residents Who Pursued Gynecologic Oncology**

<b>Name</b>	<b>Training Period</b>	<b>Fellowship Program</b>	<b>Current Position</b>
M. Dwight Chen, MD	1987-1991	University of Minnesota Hospital & Clinic	Sutter Health, Palo Alto Medical Foundation, Mountain View, CA
Albert Pisani, MD	1988-1992	Cedars-Sinai/UCLA	Sutter Health, Palo Alto Medical Foundation, Mountain View, CA
Frank Cirisano, MD	1990-1994	Duke University	Woman's Cancer Care Center, Delray Beach, FL
Hyun Sook Shvartsman, MD	1996-2000	University of Texas MD Anderson Cancer Center	Kaiser Permanente, Baldwin Park, CA
Dimitry Lerner, MD	2003-2007	Mt. Sinai Medical Center	Sutter Health, East Bay Gynecological Oncology, Walnut Creek, CA
Yevgeniya Ioffe, MD	2006-2010	Washington University School of Medicine	Loma Linda University, Loma Linda, CA
Mae Zakhour, MD	2009-2013	Cedars-Sinai/UCLA	David Geffen School of Medicine at UCLA
Arthur-Quan Tran, MD	2011-2015	UNC School of Medicine	In training
Jeanine Staples, MD	2013-2017	University of Virginia School of Medicine	In training

**Selected Mentored Post-Doctoral Students**

<b>Name</b>	<b>Training Period</b>	<b>Current Position</b>
Elizabeta Nemeth, PhD	1998-2000	Professor of Medicine at the David Geffen School of Medicine at UCLA, and Director of the UCLA Center for Iron Disorders
Franck Riquet, PhD	2005-2007	Ghent University, VIB Department of Molecular Biomedical Research, Gent Belgium
Susan Wei, PhD	2005-2008	Assistant Professor, University of Minnesota School of Public Health, Division of Biostatistics, Minneapolis, MN
Dong-Joo Ellen Cheon, PhD	2009-2015	Assistant Professor, Center for Cell Biology and Cancer Research, Albany Medical College, Albany, NY
Paul-Joseph Aspuria, PhD	2009-2015	Scientist, KITE Pharma, Inc

## Selected Mentored PhD Students

Name	Training Period	Current Position
Maricel Gozo, PhD	2008-2013	Postdoctoral Scholar, University of California, San Diego, San Diego, CA
Jessica Beach, PhD	2010-2015	Postdoctoral Fellow & Cancer Researcher, Peter MacCallum Cancer Centre, Melbourne, Australia
Raluca Kurz, MS	2013-Present	PhD Awarded 2019, UCLA School of Public Health, Los Angeles, CA

## Publications

### A. Research Articles [Peer-Reviewed]

1. **Karlan BY**, Ashman RF: Order of events leading to surface immunoglobulin capping: analysis of a transmembrane signal. *J Immunol*, 127:1177-1181, 1981.
2. Ashman RF, **Karlan BRY**: Inhibition of antigen-induced and anti-immunoglobulin-induced capping by hydrocortisone and propranolol. *Immunopharmacology*, 3(1):41-47, 1981. PMID: 6971857
3. **Karlan BY**, Clark AS, Littlefield BA: A highly sensitive chromogenic microtiter plate assay for plasminogen activators which quantitatively discriminates between the urokinase and tissue-type activators. *Biochem Biophys Res Commun*, 142(1):147-154, 1987. PMID: 3101684
4. Amin W, **Karlan BY**, Littlefield BA: Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations. *Cancer Res*, 47(22):6040-6045, 1987. PMID: 3117361
5. **Karlan BY**, Amin W, Casper SE, Littlefield BA: Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids. *Cancer Res*, 48(12):3502-3506, 1988. PMID: 3285997
6. **Karlan BY**, Amin W, Band V, Zurawski VR Jr, Littlefield BA: Plasminogen activator secretion by established lines of human ovarian carcinoma cells *in vitro*. *Gynecol Oncol*, 31(1):103-112, 1988. PMID: 3410341
7. Band V, **Karlan BY**, Zurawski VR Jr, Littlefield BA: Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells. *J Cell Physiol*, 138(1):106-114, 1989. PMID: 2492025
8. **Karlan BY**, Rivero JA, Crabtree ME, Littlefield BA: Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells. *Mol Endocrinol*, 3(6):1006-1013, 1989. PMID: 2500590
9. Trimble EL, **Karlan BY**, Lagasse LD, Hoskins WJ: Diagnosing the correct ovarian cancer syndrome. *Obstet Gynecol*, 78(6):1023-1026, 1991. PMID: 1945201
10. **Karlan BY**, Hoh C, Tse N, Futoran R, Hawkins R, Glaspy J: Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. *Gynecol Oncol*, 49(3):383-388, 1993. PMID: 8314543

11. Cirisano FD, Greenspoon JS, Stenson R, Farias-Eisner R, **Karlan BY**, Lagasse LD: The etiology and management of diarrhea in the gynecologic oncology patient. *Gynecol Oncol*, 50(1):45-48, 1993. PMID: 8349164
12. Brown JV, **Karlan BY**, Greenspoon JS, Rosove MH, Lagasse LD: Perioperative coagulopathy in patients undergoing primary cytoreduction. *Cancer*, 71(8):2557-2561, 1993. PMID: 8453579
13. **Karlan BY**, Hawkins R, Hoh C, Lee M, Tse N, Cane P, Glaspy J: Whole body positron emission tomography with 2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. *Gynecol Oncol*, 51(2):175-181, 1993. PMID: 8276290
14. **Karlan BY**, Raffel LJ, Crvenkovic G, Smrt C, Chen MD, Lopez E, Walla CA, Garber C, Cane P, Sarti DA, Rotter JI, Platt, LD: A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. *Am J Obstet Gynecol*, 169(3):494-501, 1993. PMID: 8372851
15. **Karlan BY**, Chamorro T, Fowler JM, Muderspach LI, Greenberg S, Lagasse LD: Concurrent interstitial radiotherapy and infusional chemotherapy for recurrent gynecologic malignancies. *Int J Gynecol Cancer*, 3(5):304-310, 1993. PMID: 11578362
16. **Karlan BY**, Jones J, Slamon DJ, Lagasse LD: Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. *Gynecol Oncol*, 53(1):70-77, 1994. PMID: 7909787
17. Farias-Eisner R, Cirisano FD, Grouse D, Leuchter RS, **Karlan BY**, Lagasse LD, Berek JS: Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T<sub>1-2</sub>N<sub>0-1</sub>M<sub>0</sub>) disease. *Gynecol Oncol*, 53(1):55-58, 1994. PMID: 8175023
18. Farias-Eisner R, Teng F, Oliveira M, Leuchter R, **Karlan BY**, Lagasse LD, Berek JS: The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. *Gynecol Oncol*, 55(1):108-110, 1994. PMID: 7959250
19. McGonigle KF, **Karlan BY**, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL: Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. *Gynecol Oncol*, 55(1):126-132, 1994. PMID: 7959253
20. **Karlan BY**, Marrs R., Lagasse LD: Advanced stage ovarian carcinoma presenting during infertility evaluation. *Am J Obstet Gynecol*, 171(5):1377-1378, 1994. PMID: 7977550
21. Jones J, Lagasse LD, **Karlan, BY**: Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. *Gynecol Oncol*, 55(3 pt 1):421-426, 1994. PMID: 7835782
22. **Karlan BY**, Platt LD: The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. *Gynecol Oncol*, 55(3 pt 2):S28-S33, 1994. PMID: 7835806
23. **Karlan BY**, Jones J, Greenwald M, Lagasse L: Steroid hormone effects on the proliferation of human ovarian surface epithelium *in vitro*. *Am J Obstet Gynecol*, 173(1):97-104, 1995. PMID: 7631734
24. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, **Karlan BY**: HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. *Obstet Gynecol*, 85(5 pt 1):729-734, 1995. PMID: 7724103
25. Cane P, Azen C, Lopez E, Platt LD, **Karlan BY**: Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. *Gynecol Oncol*, 57(2):240-245, 1995. PMID: 7729742

26. **Karlan BY**, Baldwin RL, Cirisano FD, Mamula PW, Jones, J, Lagasse LD: Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. *Gynecol Oncol*, 59(1):67-74, 1995. PMID: 7557618
27. **Karlan BY**: Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? *J Cell Biochem*, 23(Suppl):227-232, 1995. PMID: 8747401
28. **Karlan BY**, Platt LD: Ovarian cancer screening: the role of ultrasound in early detection. *Cancer*, 76(10 Suppl):2011-2015, 1995. PMID: 8634993
29. Casey AC, Tassin J, Greenberg S, Palmer D, Leuchter RS, Lagasse LD, **Karlan BY**: Interstitial high dose rate brachytherapy utilizing remote afterloaded polyethylene tubes and a high activity iridium-192 source for incompletely resected gynecologic malignancies. *J Gynecol Tech*, 1:201-206, 1995.
30. Cirisano FD, **Karlan BY**: The role of the HER-2/neu oncogene in gynecologic cancers. *J Soc Gynecol Investig*, 3(3):99-105, 1996. PMID: 8796816
31. Casey AC, Farias-Eisner R, Pisani AL, Cirisano FD, Kim YB, Muderspach L, Futoran R, Leuchter RS, Lagasse LD, **Karlan BY**: What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995? *Gynecol Oncol*, 60(3):454-461, 1996. PMID: 8774657
32. Bristow RE, **Karlan BY**: Ovulation induction, infertility, and ovarian cancer risk. *Fertil Steril*, 66(4):499-507, 1996. PMID: 8816606
33. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, **Karlan B**, Slamon DJ: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. *Oncogene*, 13(9):1971-1981, 1996. PMID: 8934544
34. Kim YB, Barbuto D, Lagasse LD, **Karlan BY**: Successful treatment of neuroendocrine small cell carcinoma of the cervix metastatic to regional lymph nodes. *Gynecol Oncol*, 62(3):411-414, 1996. PMID: 8812543
35. Bristow RE, Lagasse LD, **Karlan BY**: Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. *Cancer*, 78(10):2049-2062, 1996. PMID: 8918397
36. Ng WL, Schummer M, Cirisano FD, Baldwin RL, **Karlan BY**, Hood, L: High-throughput plasmid mini preparations facilitated by micro-mixing. *Nucleic Acids Res*, 24(24):5045-5047, 1996. PMID: 9016678
37. Bristow RE, **Karlan BY**: Stage IV ovarian carcinoma following ovulation induction: a report of three cases. *International J Gynecol Cancer*, 7:112-116, 1997.
38. Amir M, Shabot MM, **Karlan BY**: Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications. *Amer J Obstet Gynecol*, 176(6):1389-1393, 1997. PMID: 9215205
39. Grote TH, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, **Karlan BY**, Reeves JA, Porter LL, Benedict CR, Hahne WF: Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. *Cancer J Sci Am*, 3(1):45-51, 1997. PMID: 9072308
40. **Karlan BY**: The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. *Cancer Invest*, 15(3):265-269, 1997. PMID: 9171861
41. Abrahamson J, Moslehi R, Vesprini D, **Karlan B**, Fishman D, Smotkin D, David Y, Biran H, Fields A, Brunet JS, Narod SA: No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. *Cancer Res*, 58(14):2919-2922, 1998. PMID: 9679945



42. Hoh CK, Seltzer MA, Yong TA, Czernin J, Silverman DHS, Gambhir SS, Phelps ME, **Karlan BY**: Positron emission tomography in gynecologic malignancies. *J Gynecol Tech*, 4:19-24, 1998.
43. Descamps P, Fondrinier E, Biquard F, Binelli C, Lepinard C, Loisel D, Crvencowicz G, Platt LD, **Karlan B**: Is ultrasound screening for ovarian cancer possible in 1998? *J Gynecol Obstet Biol Reprod*, 27(5):476-481, 1998. PMID: 9791573
44. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, **Karlan BY**: Survival impact of surgical cytoreduction in Stage IV epithelial ovarian cancer. *Gynecol Oncol*, 72(3):278-287, 1999. PMID: 10053096
45. Bristow RE, Baldwin RL, Yamada SD, Korc M, **Karlan BY**: Altered expression of transforming growth factor- $\beta$  ligands and receptors in primary and recurrent ovarian carcinoma. *Cancer*, 85(3):658-668, 1999. PMID: 10091739
46. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, **Karlan B**, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: Localization of human *BRCA1* and its loss in high-grade, non-inherited breast carcinomas. *Nat Genet*, 21(2):236-240, 1999. PMID: 9988281
47. **Karlan BY**, Baldwin RL, Lopez-Luevanos E, Raffel LJ, Barbuto D, Narod S, Platt LD: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. *Am J Obstet Gynecol*, 180(4):917-928, 1999. PMID: 10203660
48. Baldwin RL, Tran H, **Karlan BY**: Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. *Gynecol Oncol*, 74(2):265-271, 1999. PMID: 10419743
49. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, **Karlan BY**, Hood L: Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. *Gene*, 238(2):375-385, 1999. PMID: 10570965
50. Yamada SD, Baldwin RL, **Karlan BY**: Ovarian carcinoma cell cultures are resistant to TGF- $\beta$ 1-mediated growth inhibition despite expression of functional receptors. *Gynecol Oncol*, 75(1):72-77, 1999. PMID: 10502429
51. Moslehi R, Chu W, **Karlan B**, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA: *BRCA1* and *BRCA2* mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. *Am J Hum Genet*, 66(4):1259-1272, 2000. PMID: 10739756
52. Chen LM, Leuchter RS, Lagasse LD, **Karlan BY**: Splenectomy and surgical cytoreduction for ovarian cancer. *Gynecol Oncol*, 77(3):362-368, 2000. PMID: 10831343
53. Crump C, McIntosh MW, Urban N, Anderson G, **Karlan BY**: Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening. *Cancer Epidemiol Biomarkers Prev*, 9(10):1107-1111, 2000. PMID: 11045795
54. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, **Karlan BY**: *BRCA1* promoter region hypermethylation in ovarian carcinoma: a population-based study. *Cancer Res*, 60(19):5329-5333, 2000. PMID: 11034065
55. Ismail RS, Baldwin RL, Fang J, Browning D, **Karlan BY**, Gasson JC, Chang DD: Differential gene expression between normal and tumor-derived ovarian epithelial cells. *Cancer Res*, 60(23):6744-6749, 2000. PMID: 11118061

56. Brown JV 3<sup>rd</sup>, Peters WA 3<sup>rd</sup>, Rettenmaier MA, **Karlan BY**, Dillman RA, Smith MR, Drescher CW, Micha JP: A phase I trial of a three day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube and peritoneum. *Gynecol Oncol*, 79(3):495-498, 2000. PMID: 11104627
57. Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, **Karlan B**, Warner E, Rosen B, Rebbeck T, Tonin P, Dube MP, Kieback DG, Narod SA: Progesterone receptor variant increases ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers who were never exposed to oral contraceptives. *Pharmacogenetics*, 11(7):635-638, 2001. PMID: 11668223
58. Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, **Karlan BY**: Pattern of lymph node metastases in clinically unilateral stage 1 invasive epithelial ovarian carcinomas. *Gynecol Oncol*, 80(1):56-61, 2001. PMID: 11136570
59. Cass I, Baldwin RL, Fasylova E, Fields AL, Klinger HP, Runowicz CD, **Karlan BY**: Allelotype of papillary serous peritoneal carcinomas. *Gynecol Oncol*, 82(1):69-76, 2001. PMID: 11426964
60. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, **Karlan B**, Fishman D, Rosen B, Tung N, Neuhausen SL: Tubal ligation and risk of ovarian cancer in carriers of *BRCA1* or *BRCA2* mutations: a case-control study. *Lancet*, 357(9267):1467-1470, 2001. PMID: 11377596
61. McIntosh MW, Urban N, **Karlan B**: Generating longitudinal screening algorithms using novel biomarkers for disease. *Cancer, Epidemiol Biomarkers & Prev*, 11(2):159-166, 2002. PMID: 11867503
62. Liede A, **Karlan BY**, Baldwin RL, Platt LD, Kuperstein G, Narod SA: Cancer incidence in a population of Jewish women at risk of ovarian cancer. *J Clin Oncol*, 20(6):1570-1577, 2002. PMID: 11896106
63. Gillan L, Matei D, Fishman DA, Gerbin CS, **Karlan BY**, Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for  $\alpha\beta3$  and  $\alpha\beta5$  integrins and promotes cell motility. *Cancer Res*, 62(18):5358-5364, 2002. PMID: 12235007
64. Matei D, Graeber TG, Baldwin RL, **Karlan BY**, Rao J, Chang DD: Gene expression in epithelial ovarian carcinoma. *Oncogene*, 21(41):6289-6298, 2002. PMID: 12214269
65. Buller RE, Runnebaum IG, **Karlan BY**, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M: A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. *Cancer Gene Therapy*, 9(7):553-566, 2002. PMID: 12082455
66. Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, **Karlan B**, Slamon D, Pegram M: Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. *Cancer Gene Therapy*, 9(7):567-572, 2002. PMID: 12082456
67. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, **Karlan BY**: A human ovarian carcinoma murine xenograft model useful for preclinical trials. *Gynecol Oncol*, 87(2):200-206, 2002. PMID: 12477452
68. Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, **Karlan BY**, Berek JS, Farias-Eisner R: FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. *Int J Gynecol Cancer*, 12(5):454-458, 2002. PMID: 12366662
69. **Karlan BY**, Boyd J, Strong L, Garber J, Fountain J, Beller U: Hereditary ovarian cancer. *Gynecol Oncol*, 88:S11-S13, 2003.
70. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, **Karlan BY**: Improved survival in women with *BRCA*-associated ovarian carcinoma. *Cancer*, 97(9):2187-2195, 2003. PMID: 12712470

71. Baldwin RL, Tran H, **Karlan BY**: Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. *Cancer Res*, 63(6):1413-1419, 2003. PMID: 12649207
72. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, **Karlan BY**, Slamon DJ: Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. *Cancer Res*, 63(1):196-206, 2003. PMID: 12517798
73. Li AJ, Baldwin RL, **Karlan BY**: Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. *Clin Cancer Res*, 9(10 Pt 1):3667-3673, 2003. PMID: 14506156
74. Li AJ, Baldwin RL, **Karlan BY**: Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. *Amer J Obstet Gynecol*, 189(1):22-27, 2003. PMID: 12861133
75. Chen LM, Yamada SD, Fu YS, Baldwin RL, **Karlan BY**: Molecular similarities between primary peritoneal and primary ovarian carcinomas. *Int J Gynecol Cancer*, 13(6):749-755, 2003. PMID: 14675310
76. Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA Wheeler JE, Wonderlick A, Fishman D, **Karlan B**, Risch H, Cramer DW, Dube MP, Narod SA: Reproductive factors and ovarian cancer risk in Jewish *BRCA1* and *BRCA2* mutation carriers (United States). *Cancer Causes Control*, 14(5):439-446, 2003. PMID: 12946038
77. Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, **Karlan BY**: The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. *Gynecol Oncol*, 92(1):211-214, 2004. PMID: 14751160
78. Liede A, **Karlan BY**, Narod SA: Cancer risks for male carriers of germline mutations in *BRCA1* or *BRCA2*: a review of the literature. *J Clin Oncol*, 22(4):735-742, 2004. PMID: 14966099
79. McIntosh MW, Drescher C, **Karlan B**, Scholler N, Urban N, Hellstrom KE, Hellstrom I: Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. *Gynecol Oncol*, 95(1):9-15, 2004. PMID: 15385104
80. Agus DB, Gordon MS, Taylor C, Natale RB, **Karlan B**, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. *J Clin Oncol*, 23(11):2534-2543, 2005. PMID: 15699478
81. Elkas JC, Berek JS, Leuchter R, Lagasse LD, **Karlan BY**: Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies. *Gynecol Oncol*, 97(2):685-692, 2005. PMID: 15863183
82. Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Issacs C, Weber B, . . . **Karlan B**, . . . et al: Age at menarche and the risk of breast cancer in *BRCA1* and *BRCA2* mutation carriers. *Cancers Causes and Control*, 16(6):667-674, 2005. PMID: 16049805
83. Holschneider CH, Baldwin RL, Tumber K, Aoyama C, **Karlan BY**: The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer. *Clin Cancer Res*, 11(16):5756-5763, 2005. PMID: 161115913
84. Walsh C, Holschneider C, Hoang Y, Tieu K, **Karlan B**, Cass I: Coexisting ovarian malignancy in young women with endometrial cancer. *Obstet Gynecol*, 106(4):693-699, 2005. PMID: 16199623

85. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, **Karlan BY**, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. *Int J Cancer*, 117(6):1049-1054, 2005. PMID: 15963183
86. Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, **Karlan BY**: Ovarian preservation in stage I low-grade endometrial stromal sarcomas. *Obstet Gynecol*, 106(6):1304-1308, 2005. PMID: 16319256
87. Li AJ, **Karlan BY**: Androgen mediation of thrombocytosis in epithelial ovarian cancer biology. *Clin Cancer Res*, 11(22):8015-8018, 2005. PMID: 16299230
88. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, **Karlan BY**: *BRCA*-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? *Obstet Gynecol*, 106(6):1327-1334, 2005. PMID: 16319259
89. Li AJ, Lerner DL, Gapuzan ME, **Karlan BY**: AIB1 polymorphisms predict aggressive ovarian cancer phenotype. *Cancer, Epidemiol, Biomarkers & Prev*, 14(12):2919-2922, 2005. PMID: 16365010
90. Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, **Karlan B**, Sun P, Narod SA: Hormone replacement therapy and the risk of ovarian cancer in *BRCA1* and *BRCA2* mutation carriers. *Gynecol Oncol*, 100(1):83-88, 2006. PMID: 16137751
91. Chiang JW, **Karlan BY**, Cass I, Baldwin RL: *BRCA1* promoter methylation predicts adverse ovarian cancer prognosis. *Gynecol Oncol*, 101(3):403-410, 2006. PMID: 16360812
92. Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, Li L, . . . **Karlan BY**, . . . et al: Prognostic DNA methylation biomarkers in ovarian cancer. *Clin Cancer Res*, 12(9):2788-2794, 2006. PMID: 16675572
93. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, . . . **Karlan B**, . . . et al: Spontaneous and therapeutic abortions and the risk of breast cancer among *BRCA* mutation carriers. *Breast Cancer Res*, 8(2):R15,1-7, 2006. PMID: 16563180
94. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, . . . **Karlan B**, . . . et al: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a *BRCA1* or *BRCA2* mutation. *JAMA*, 296(2):185-192, 2006. PMID: 16835424
95. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, **Karlan BY**, Koeffler HP: 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. *Cancer Res*, 66(15):7818-7823, 2006. PMID: 16885386
96. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, **Karlan BY**: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. *J Clin Oncol*, 24(26):4324-4332, 2006. PMID: 169896006
97. Guillem JG, Wood WC, Moley JF, Berchuck A, **Karlan BY**, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. *Ann Surg Oncol*, 13(10):1296-1321, 2006. PMID: 16990987
98. Guillem JG, Wood WC, Moley JF, Berchuck A, **Karlan BY**, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. *J Clin Oncol*, 24(28):4642-4660, 2006. PMID: 17008706

99. Benbrook DM, **Karlan BY**: Promise and problems of translational research. *Gynecol Oncol*, 103:S14-S17, 2006.
100. Pavelka JC, Brown RS, **Karlan BY**, Cass I, Leuchter RS, Lagasse LD, Li AJ: Effect of obesity on survival in epithelial ovarian cancer. *Cancer*, 107(7):1520-1524, 2006. PMID: 16941453
101. Wolf I, Bose S, Williamson EA, Miller CW, **Karlan BY**, Koeffler HP: FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. *Int J Cancer*, 120(5):1013-1022, 2007. PMID: 17163418
102. Lerner DL, Walsh CS, Cass I, **Karlan BY**, Li AJ: The prognostic significance of thrombocytosis in uterine papillary serous carcinomas. *Gynecol Oncol*, 104(1):91-94, 2007. PMID: 16934317
103. Scoles DR, Pavelka J, Cass I, Tran H, Baldwin RL, Armstrong K, **Karlan BY**: Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. *Gynecol Oncol*, 104(1):120-128, 2007. PMID: 16956650
104. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, **Karlan B**, et al: Reproductive risk factors for ovarian cancer in carriers of *BRCA1* or *BRCA2* mutations: a case-control study. *Lancet Oncol*, 8(1):26-34, 2007. PMID: 17196508
105. Karam AK, Santillan A, Bristow RE, Giuntoli R 2<sup>nd</sup>, Gardner GJ, Cass I, **Karlan BY**, Li AJ: Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. *Gynecol Oncol*, 104(2):377-380, 2007. PMID: 17014899
106. Walsh CS, Miller CW, **Karlan BY**, Koeffler HP: Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. *Gynecol Oncol*, 104(3):660-664, 2007. PMID: 17123590
107. Santillan A, Karam AK, Li AJ, Giuntoli R 2<sup>nd</sup>, Gardner GJ, Cass I, **Karlan BY**, Bristow RE: Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. *Gynecol Oncol*, 104(3):686-690, 2007. PMID: 17141302
108. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, **Karlan BY**, Holschneider CH: Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. *J Clin Oncol*, 25(4):384-389, 2007. PMID: 17264334
109. Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, **Karlan BY**, Arbiser JL, Koeffler HP: Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. *Int J Oncol*, 30(6):1529-1537, 2007. PMID: 17487375
110. Kotsopoulos J, Ghadirian P, El-Sohemy A, Lynch HT, Snyder C, Daly M, Domchek S, . . . **Karlan B**, . . . et al: The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among *BRCA1* mutation carriers. *Cancer Epidemiol Biomarkers Prev*, 16(5):912-916, 2007. PMID: 17507615
111. **Karlan BY**, Berchuck A, Mutch D: The role of genetic testing for cancer susceptibility in gynecologic practice. *Obstet Gynecol*, 110(1):155-167, 2007. PMID: 17601911
112. Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, **Karlan BY**, Koeffler HP: Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. *Breast Cancer Res Treat*, 105(2):139-155, 2007. PMID: 17295047

113. Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, . . . **Karlan B**, . . . et al: Age at first birth and the risk of breast cancer in *BRCA1* and *BRCA2* mutation carriers. *Breast Cancer Res Treat*, 105(2):221-228, 2007. PMID: 17245541
114. Li AJ, Elmore RG, Pavelka JC, **Karlan BY**: Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. *Gynecol Oncol*, 107(3):420-423, 2007. PMID: 17825390
115. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, **Karlan BY**, Herzog TJ, Society of Gynecologic Oncologists Education Committee: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol*, 107(2):159-162, 2007. PMID: 17950381
116. Sakai W, Swisher EM, **Karlan BY**, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T: Secondary mutations as a mechanism of cisplatin resistance in *BRCA2*-mutated cancers. *Nature*, 451(7182):1116-1120, 2008. PMID: 18264087
117. Swisher EM, Sakai W, **Karlan BY**, Wurz K, Urban N, Taniguchi T: Secondary *BRCA1* mutations in *BRCA1*-mutated ovarian carcinomas with platinum resistance. *Cancer Res*, 68(8):2581-2586, 2008. PMID: 18413725
118. Li AJ, Scoles DR, Armstrong KU, **Karlan BY**: Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. *Gynecol Oncol*, 109(2):220-225, 2008. PMID: 18374401
119. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, **Karlan BY**: ERCC5 is a novel biomarker of ovarian cancer prognosis. *J Clin Oncol*, 26(18):2952-2958, 2008. PMID: 18565881
120. O'Kelly J, Chung A, Lemp N, Chumakova K, Yin D, Wang HJ, Said J, Gui D, Miller CW, **Karlan BY**, Koeffler HP: Functional domains of CCN1 (Cyr61) regulate breast cancer progression. *Int J Oncol*, 33(1):59-67, 2008. PMID: 18575751
121. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, . . . **Karlan B**, . . . et al: Rapid progression of prostate cancer in men with a *BRCA2* mutation. *Br J Cancer*, 99(2):371-374, 2008. PMID: 18577985
122. Wakimoto N, Yin D, O'Kelly J, Haritunians T, **Karlan B**, Said J, Xing H, Koeffler HP: Cucurbitacin B has a potent antiproliferative effect on breast cancer cells *in vitro* and *in vivo*. *Cancer Sci*, 99(9):1793-1797, 2008. PMID: 18627377
123. Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, **Karlan B**, Slamon DJ: Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. *Genes Chromosomes Cancer*, 47(10):873-883, 2008. PMID: 18615678
124. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, **Karlan B**, Kaufman B, Koeffler HP, Rubinek T: Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. *Oncogene*, 27(56):7094-7105, 2008. PMID: 18762812
125. Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, Koeffler HP, **Karlan BY**: Genome-wide loss of heterozygosity and uniparental disomy in *BRCA1/2*-associated ovarian carcinomas. *Clin Cancer Res*, 14(23):7645-7651, 2008. PMID: 19047089

126. Li AJ, **Karlan BY**: Androgens and epithelial ovarian cancer: What's the connection? *Cancer Biol Therapy*, 7(11):1712-1716, 2008. PMID: 19151584
127. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, . . . **Karlan BY**, . . . et al.: Hormone therapy and the risk of breast cancer in *BRCA1* mutation carriers. *J Natl Cancer Inst*, 100(19):1361-1367; 2008. PMID: 18812548
128. Elmore RG, Ioffe Y, Scoles DR, **Karlan BY**, Li AJ: Impact of statin therapy on survival in epithelial ovarian cancer. *Gynecol Oncol*, 111(1):102-105, 2008. PMID: 20698078
129. Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, . . . **Karlan BY**, . . . et al.: Infertility, treatment of infertility, and the risk of breast cancer among women with *BRCA1* and *BRCA2* mutations: a case-control study. *Cancer Causes Control*, 19(10):1111-1119; 2008. PMID: 18509731
130. Winer E, Gralow J, Diller L, **Karlan B**, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL, American Society of Clinical Oncology: Clinical Cancer Advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. *J Clin Oncol*, 27(5):812-826, 2009. PMID: 19103723
131. Karam AK, Chiang JW, Fung E, Nossov V, **Karlan BY**: Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. *Gynecol Oncol*, 114(2):246-252, 2009. PMID: 19500821
132. Vicus D, Rosen B, Lubinski J, Domchek S, Kauff ND, Lynch HT, Isaacs C, . . . **Karlan BY**, . . . et al.: Tamoxifen and the risk of ovarian cancer in *BRCA1* mutation carriers. *Gynecol Oncol*, 115(1):135-137; 2009. PMID: 19577280
133. Ioffe YJM, Xing D, Aspuria P-J, **Karlan B**, Orsulic S: A preclinical mouse model for uterine leiomyosarcoma. *Electronic Update Sarcoma Newsletter* 6(4), 2009.
134. Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJM, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, **Karlan BY**, Mohapatra G, Orsulic S: A role for *BRCA1* in uterine leiomyosarcoma. *Cancer Res*, 69(21):8231-8235, 2009. PMID: 19843854
135. Ioffe YJ, Li AJ, Walsh CS, **Karlan BY**, Leuchter R, Forscher C, Cass I: Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. *Gynecol Oncol*, 115(3):466-471, 2009. PMID: 19767065
136. Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, . . . **Karlan BY**, et al.: Smoking and the risk of breast cancer in *BRCA1* and *BRCA2* carriers: an update. *Breast Cancer Res Treat*, 114(1):127-135; 2009. PMID: 18483851
137. Li AJ, Elmore RG, Chen IY, **Karlan BY**: Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. *Gynecol Oncol*, 116(1):78-81, 2010. PMID: 19822357
138. Li AJ, McAllister P, **Karlan BY**: Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in *BRCA* mutation-associated epithelial ovarian cancers. *Gynecol Oncol*, 116(1):105-108, 2010. PMID: 19818997
139. Scoles DR, Xu X, Wang H, Tran H, Taylor-Harding B, Li A, **Karlan BY**: Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. *Gynecol Oncol*, 116(1):109-116, 2010. PMID: 19854496

140. Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, Ventura AP, Godwin AK, **Karlan BY**, Drescher CW, Urban N, Knudsen BS, Tewari M: Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. *Gynecol Oncol*, 116(1):117-125, 2010. PMID: 19854497
141. Pal T, Keefe D, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group. . . **Karlan BY**. . . et al: Fertility in women with *BRCA* mutations: a case-control study. *Fertil Steril*, 93(6):1805-1808; 2010. PMID: 19200971
142. Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, **Karlan BY**, Friedman E, Kaufman B: Functional variant of *KLOTHO*: a breast cancer risk modifier among *BRCA1* mutation carriers of Ashkenazi origin. *Oncogene*, 29(1):26-33, 2010. PMID: 19802015.
143. Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, Leiter A, **Karlan B**, Mehta R, Koeffler HP: Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and negative breast cancer cells by modulating the EGFR/HER-2 pathway. *Oncogene*, 29(2):285-296, 2010. PMID: 19855437.
144. Walsh CS, **Karlan BY**: Molecular signatures of ovarian cancer: from detection to prognosis. *Mol Diagn Ther*, 14(1):13-22, 2010. PMID: 20121286.
145. Schummer M, Green A, Beatty JD, **Karlan BY**, Karlan S, Gross J, Thornton S, McIntosh M, Urban N: Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection. *PLoS One*, 5(2):e9122, 2010. PMID: 20161755.
146. Walsh CS, Blum A, Walts A, Alsabeh R, Tran H, Koeffler HP, **Karlan BY**: Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening. *Gynecol Oncol*, 116(3):516-521, 2010. PMID: 20034658.
147. Mercado C, Zingmond D, **Karlan BY**, Sekaris E, Gross J, Maggard-Gibbons M, Tomlinson JS, Ko CY: Quality of care in advanced ovarian cancer: the importance of provider specialty. *Gynecol Oncol*, 117(1):18-22, 2010. PMID: 20106512
148. Cass I, Walts A, **Karlan BY**. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? *Gynecol Oncol*, 117(1):27-31, 2010. PMID: 20110118
149. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, **Karlan BY**, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK: Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. *Cancer*, 116(8):1918-1925, 2010. PMID: 20166213
150. Karam AK, **Karlan BY**: Ovarian cancer: the duplicity of CA125 measurement. *Nat Rev Clin Oncol*, 7(6):335-339, 2010. PMID: 20368726
151. Konstantinopoulos PA, Spentzos D, **Karlan BY**, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA: Gene expression profile of *BRCA*ness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. *J Clin Oncol*, 28(22):3555-3561, 2010. PMID: 20547991
152. Ioffe YJ, Elmore RG, **Karlan BY**, Li AJ: Effect of cigarette smoking on epithelial ovarian cancer survival. *J Reprod Med*, 55(7-8):346-350, 2010. PMID: 2079535
153. Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, **Karlan B**, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group: Risk factors for carcinoma of the fallopian tube in women with and without a germline *BRCA* mutation. *Gynecol Oncol*, 118(2):155-159; 2010. PMID: 20452659



154. Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, Royer R, McLaughlin J, **Karlan B**, Narod SA: Prevalence of *BRCA1* and *BRCA2* germ line mutations among women with carcinoma of the fallopian tube. *Gynecol Oncol*, 118(3):299-302; 2010. PMID: 20570322
155. Ibrahim N, He L, Leong CO, Xing D, **Karlan BY**, Swisher EM, Rueda BR, Orsulic S, Ellisen LW: *BRCA1*-Associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. *Cancer Res*, 70(18):7155-7165; 2010. PMID: 20807817
156. Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O'Briant K, Schummer M, **Karlan B**, Urban N, Tewari M, Drescher C, Knudsen BS: Activation of the MEK-S6 pathway in high-grade ovarian cancers. *Appl Immunohistochem Mol Morphol*, 18(6):499-508; 2010. PMID: 20661131
157. Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, Gasson JC, **Karlan BY**, Slamon DJ: Periostin promotes ovarian cancer angiogenesis and metastasis. *Gynecol Oncol*, 119(2):337-344; 2010. PMID: 20688362
158. Taylor-Harding B, Orsulic S, **Karlan BY**, Li AJ: Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. *Gynecol Oncol*, 119(3):549-556; 2010. PMID: 20837358
159. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick TM, . . . **Karlan BY**, et al.: A locus on 19p13 modifies risk of breast cancer in *BRCA1* mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet*, 42(10):885-892; 2010. PMID: 20852631
160. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, . . . **Karlan BY**, et al.: Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genet*, 42(10):880-884; 2010. PMID: 20852633
161. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, . . . **Karlan B**, . . . et al. Common breast cancer susceptibility alleles and the risk of breast cancer for *BRCA1* and *BRCA2* mutation carriers: implications for risk prediction. *Cancer Res*, 70(23):9742-9754; 2010. PMID: 21118973
162. Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, Akin D, Yan X, Chia D, **Karlan B**, Wong DT: Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. *PLoS ONE*, 5(12):e15573; 2010. PMID: 21217834
163. Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, . . . **Karlan BY**, . . . et al.: Family history of cancer and cancer risks in women with *BRCA1* or *BRCA2* mutations. *J Natl Cancer Inst*, 102(24):1874-1878; 2010. PMID: 21098759
164. Ginsberg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group, **Karlan BY**, . . . et al.: *BRCA1* and *BRCA2* families and the risk of skin cancer. *Familial Cancer*, 9(4):489-493; 2010. PMID: 20809262
165. Fleming ND, Lentz SE, Cass I, Li AJ, **Karlan, BY**, Walsh CS: Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma? *Gynecol Oncol*, 120(2):189-192; 2011. PMID: 21112078
166. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, . . . **Karlan BY**, et al.: Genetic variation at 9p22.2 and ovarian cancer risk for *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst*, 103(2):105-116; 2011. PMID: 21169536

167. Fleming ND, Cass I, Walsh CS, **Karlan BY**, Li AJ: CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. *Gynecol Oncol*, 121(2):249-252; 2011. PMID: 21300398
168. Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D, **Karlan B**, Vadgama J, Lyons KM, Koeffler HP: Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. *Int J Oncol*, 38(6):1741-1747; 2011. PMID: 21455569
169. Fejzo MS, Ginther C, Dering J, Anderson L, Venkatesan N, Konecny G, **Karlan B**, Slamon DJ: Knockdown of ovarian cancer amplification target *ADRM1* leads to downregulation of *GIPCI* and upregulation of *RECK*. *Genes Chromosomes Cancer*, 50(6):434-441; 2011. PMID: 21432940
170. Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, . . . **Karlan BY**, . . . et al.: Diabetes and breast cancer among women with *BRCA1* and *BRCA2* mutations. *Cancer*, 117(9):1812-1818; 2011. PMID: 21509758
171. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver HA, Antonenkova N, Antoniou AC, . . . **Karlan BY**, . . . et al.: The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clin Cancer Res*, 17(11):3742-3750; 2011. PMID: 21385923
172. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, . . . **Karlan BY**, . . . et al.: Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for *BRCA1* and *BRCA2* mutation carriers. *Hum Mol Genet*, 20(16):3304-3321; 2011. PMID: 21593217
173. Amankwah EK, Wang Q, Schildkraut JM, Tsai Y-Y, Ramus SJ, Fridley BL, Beesley J, . . . **Karlan BY**, et al.: Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: A report from the Ovarian Cancer Association Consortium. *PLoS One*, 6(5):e19642; 2011. PMID: 21637745
174. Zhu M, Saxton RE, Ramos L, Chang DD, **Karlan BY**, Gasson JC, Slamon DJ: Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. *Mol Cancer Ther*, 10(8):1500-1508; 2011. PMID: 21670235
175. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO. . . **Karlan BY**, et al.: Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. *Clin Cancer Res*, 17(16):5490-5500; 2011. PMID: 21705454
176. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, **Karlan BY**, Taniguchi T, Swisher EM: Secondary somatic mutations restoring *BRCA1/2* predict chemotherapy resistance in hereditary ovarian carcinomas. *J Clin Oncol*, 29(22):3008-3015; 2011. PMID: 21709188
177. Cancer Genome Atlas Research Network (**Karlan BY**): Integrated genomic analyses of ovarian carcinoma. *Nature*, 474(7353):609-615; 2011. PMID: 21720365
178. Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, . . . **Karlan BY**, . . . et al.: Assessment of hepatocyte growth factor in ovarian cancer mortality. *Cancer Epidemiol Biomarkers Prev*, 20(8):1638-1648; 2011. PMID: 21724856
179. Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, Colton T, . . . **Karlan BY**, et al: Adverse health outcomes in women exposed in utero to diethylstilbestrol. *N Engl J Med*, 365(14):1304-1314; 2011. PMID: 21991952

180. Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ. . .**Karlan BY**, et al: Common breast cancer susceptibility alleles are associated with tumor subtypes in *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2*. *Breast Cancer Res*, 13(6):R110; 2011. PMID: 22053997
181. Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, **Karlan B**, Rubin SC: A high response rate to liposomal doxorubicin is seen among women with *BRCA* mutations treated for recurrent epithelial ovarian cancer. *Gynecol Oncol*, 123(3):486-491; 2011. PMID: 21945552
182. Lu JF, Rasmussen E, **Karlan BY**, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun YN: Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. *Cancer Chemother Pharmacol*, 69(5):1135-1144; 2012. PMID: 22210018
183. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, **Karlan BY**, Amnon A, Bell-McGuinn KM, et al.: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer. *J Clin Oncol*, 30(4):372-379; 2012. PMID: 22203755
184. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ. . . **Karlan BY**, et al: Pathology of breast and ovarian cancers among *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). *Cancer Epidemiol Biomarkers Prev*, 21(1):134-147; 2012. PMID: 22144499
185. Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, **Karlan BY**, Walsh CS: Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. *Cancer*, 118(3):689-697; 2012. PMID: 21751198
186. Zajchowski DA, **Karlan BY**, Shawver LK: Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. *Mol Cancer Ther*, 11(2):492-502; 2012. PMID: 22203729
187. Taylor-Harding B, Agadjanian H, Nassanian H, Kwon S, Guo X, Miller C, **Karlan BY**, Orsulic S, Walsh CS: Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. *Br J Cancer*, 106(2):333-343; 2012. PMID 22166800
188. **Karlan BY**, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, et al: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. *J Clin Oncol*, 30(4):362-371; 2012. PMID: 22184370
189. Painovich JM, Shufelt CL, Azziz R, Yang Y, Goodarzi MO, Braunstein GD, **Karlan BY**, Stewart PM, Merz, CN: A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause. *Menopause*, 19(1):54-61; 2012. PMID: 21968279
190. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, **Karlan BY**, Lambrechts D, et al: Association between *BRCA1* and *BRCA2* mutations and survival in women with invasive epithelial ovarian cancer. *JAMA*, 307(4):382-390; 2012. PMID: 22274685
191. Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, . . .**Karlan BY**, . . . et al: Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. *PLoS ONE*, 7(2):e30996; 2012. PMID: 22355333

192. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, . . . **Karlan BY**, . . . et al.: Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev*, 21(4):645-657; 2012. PMID: 22351618
193. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, . . . , **Karlan BY**, . . . et al: Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for *BRCA1* and/or *BRCA2* mutation carriers. *Breast Cancer Res*, 14(1):R33; 2012. PMID: 22348646
194. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L. . . **Karlan BY**. . . et al: Ovarian cancer susceptibility alleles and risk of ovarian cancer in *BRCA1* and *BRCA2* mutation carriers. *Hum Mutat* 33(4):690-702; 2012. PMID: 22253144
195. McGee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung N, Kim-Sing C, **Karlan B**, Foulkes WD, Ainsworth P, Ghadirian P, Senter L, Eisen A, Sun P, Narod SA: Anthropometric measures and risk of ovarian cancer among *BRCA1* and *BRCA2* mutation carriers. *Obesity*, 20(6):1288-1292; 2012. PMID: 22262156
196. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B. . . **Karlan BY**. . . et al.: A nonsynonymous polymorphism in *IRS1* modifies risk of developing breast and ovarian cancers in *BRCA1* and ovarian cancer in *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 21(8):1362-1370; 2012. PMID: 22729394
197. Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, **Karlan B**, Greene MI, Wang Q: YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. *Oncogene* 32:2220-2229; 2013. PMID: 22689061
198. Diaz ES, **Karlan BY**, Li AJ: Impact of beta blockers on epithelial ovarian cancer survival. *Gynecol Oncol* 127(2):375-378; 2012. PMID: 22819786
199. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD,. . . **Karlan B**, . . . et al.: Oophorectomy after menopause and the risk of breast cancer in *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 21(7):1089-1096; 2012 PMID: 22564871
200. Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, . . . **Karlan BY**, . . . et al: The risk of breast cancer in women with a *BRCA1* mutation from North America and Poland. *Int J Cancer* 131(1):229-234; 2012. PMID: 21834074
201. Urban N, Thorpe JD, **Karlan BY**, McIntosh MW, Palomares MR, Daly MB, Paley PJ, Drescher CW: Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. *Cancer Epidemiol Biomarkers Prev*, 21(11):2087-2094; 2012. PMID: 22962406
202. Kaye S, Fehrenbacher L, Holloway R, Amit A, **Karlan B**, Poznanski J, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC: A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third or complete remission. *Clin Cancer Res* 18(23):6509-6518; 2012. PMID: 23032746
203. Wenzel L, Osann K, Gross J, Kurz R, Hsieh S, Nelson, EL, **Karlan B**: Biopsychological stress factors in *BRCA* mutation carriers. *Psychosomatics* 53(6):582-590; 2012. PMID: 23157996
204. Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, . . . **Karlan BY**, . . . et al: The incidence of pancreatic cancer in *BRCA1* and *BRCA2* mutation carriers. *Br J Cancer* 107(12):2005-2009; 2012. PMID: 23099806

205. Singh K, Lester J, **Karlan BY**, Bresee C, Geva T, Gordon O: Impact of family history on choosing risk-reducing surgery among *BRCA* mutation carriers. *Amer J Obstet Gynecol* 208(4):3259.e1-6; 2013. PMID: 23333547
206. Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, Lester J, **Karlan BY**, Chen L: Long term follow up of *BRCA1* and *BRCA2* mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. *Gynecol Oncol* 129(2):364-371; 2013. PMID: 23391663
207. Diaz ES, **Karlan BY**, Li AJ: Obesity-associated adipokines correlate with survival in epithelial ovarian cancer. *Gynecol Oncol* 129(2):353-357; 2013. PMID: 23402904
208. Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, Neuhausen SL, . . . **Karlan B**, . . . et al: Frequency of premature menopause in women who carry a *BRCA1* or *BRCA2* mutation. *Fertil Steril* 99(6):1724-1728; 2013. PMID: 23414920
209. The Cancer Genome Atlas Research Network: Integrated genomic characterization of endometrial carcinoma. *Nature* 497:67-73; 2013. PMID: 23636398
210. Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, . . . **Karlan B**, . . . et al.: The incidence of endometrial cancer in women with *BRCA1* and *BRCA2* mutations: An international prospective cohort study. *Gynecol Oncol* 130(1):127-131; 2013. PMID: 23562522
211. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, . . . **Karlan BY**, . . . et al.: Genome-wide association study in *BRCA1* mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet* 2013 Mar 9(3):c1003212. PMID: 23544013
212. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, . . . **Karlan BY**, . . . et al.: Multiple independent variants at the *TERT* locus are associated with Telomere length and risks of breast and ovarian cancer. *Nat Genet* 45(4):371-384; 2013. PMID: 23535731
213. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, . . . **Karlan BY**, . . . et al.: GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet* 45(4):362-370; 2013. PMID: 23535730
214. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS. . . **Karlan BY**, . . . et al: Epigenetic analysis leads to identification of *HNF1B* as a subtype-specific susceptibility gene for ovarian cancer. *Nat Commun* 4:1628; 2013. PMID: 23535649
215. Gozo M, Aspuria P-J, Cheon D-J, Walts AE, Berel D, Miura N, **Karlan BY**, Orsulic S: FoxC2 induces *Wnt4* and *Bmp4* expression during muscle regeneration and osteogenesis. *Cell Death Differ* 20(8):1032-1042; 2013. PMID: 23707665
216. Permuth-Wey J, Lawrenson K, Shen HW, Welkova A, Tyrer JP, Chen Z, Lin H-Y, . . . **Karlan BY**, . . . et al.: Identification and molecular characterization of a novel ovarian cancer susceptibility locus at 17q21.31. *Nat Commun* 4:1627; 2013. PMID: 23535648
217. White, K, Vierkant R, Fogarty Z, Charbonneau B, Block M, Pharoah P, Chenevix-Trench G, . . . **Karlan BY**, . . . et al: Analysis of over 10,000 cases finds with no association between previous-reported candidate polymorphisms and ovarian cancer outcome. *Cancer Epidemiol Biomarkers Prev* 22(5):987-992; 2013. PMID: 23513043
218. Monk BJ, Lambrechts S, Minion L, Devoogdt N, **Karlan BY**, Vergote IB: Incidence and management of edema associated with trebananib (AMB 386). *Gynecol Oncol* 130(3):636-641; 2013. PMID: 23707665

219. Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, . . . **Karlan BY**, . . . et al: Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. *Proc Natl Acad Sci USA* 110(15):6109-6114; 2013. PMID: 2356305
220. Senst N, Llacuachaqui M, Lubinski J, Lynch H, Armel S, Neuhausen S, Ghadirian P,. . . **Karlan BY**, . . . et al: Parental origin of mutation and the risk of breast cancer in a prospective study of women with a *BRCA1* or *BRCA2* mutation. *Clin Genet* 84(1):43-46; 2013.
221. Johnatty SE, Beesley J, Gao B, Chen X, Lu Y, Law MH, Henderson MJ, . . . **Karlan BY**, . . . et al: ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Consortium and The Cancer Genome Atlas. *Gynecol Oncol* 131(1):8-14; 2013. PMID: 23917080
222. Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, . . . Hereditary Breast Cancer Clinical Study Group (**Karlan BY**): International rates of breast reconstruction after prophylactic mastectomy in *BRCA1* and *BRCA2* mutation carriers. *Ann Surg Oncol* 20(12):3817-3822; 2013. PMID: 23740344
223. Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, . . . Hereditary Breast Cancer Clinical Study Group (**Karlan BY**): The impact of pregnancy on breast cancer survival in women who carry a *BRCA1* or *BRCA2* mutation. *Breast Cancer Res Treat* 142(1):177-185; 2013. PMID: 24136669
224. Zakhour M, Li AJ, Walsh C, Cass I, **Karlan BY**, Rimel BJ: Post treatment surveillance of type II endometrial cancer patients. *Gynecol Oncol* 131(3):609-12; 2013. PMID: 24051222
225. Diaz E, Walts AE, **Karlan BY**, Walsh CS: Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. *Gynecol Oncol* 131(3):541-545; 2013. PMID: 24041880
226. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer Study; Australian Ovarian Cancer Study Group,. . . **Karlan BY**, . . . et al: Genome-wise association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Hum Genet* 133(5):481-497; 2014. PMID: 24190013
227. Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Beach JA, Lester J, Tighiouart M, Walts A, **Karlan BY**, Orsulic S: A collagen-remodeling gene signature regulated by TGF- $\beta$  signaling is associated with metastasis and poor survival in serous ovarian cancer. *Clin Cancer Res* 20(3):711-723; 2014. PMID: 24218511
228. Charbonneau B, Block MS, Bamlet WR, Viekant RA, Kalli KR, Fogarty Z, Rider DN,. . . **Karlan BY**, . . . et al: Risk of ovarian cancer and the NF- $\kappa$ B Pathway: Genetic association with IL1A and TNFSF10. *Cancer Res* 74(3):852-861; 2014. PMID: 24272484
229. **Karlan BY**, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D: *POSTN/TGFBI*-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. *Gynecol Oncol* 132(2):334-342; 2014. PMID: 24368280
230. Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P,. . . **Karlan B**, . . . et al: Incidence of colorectal cancer in *BRCA1* and *BRCA2* mutation carriers: results from a follow-up study. *Br J Cancer* 110(2):530-534; 2014. PMID: 24292448
231. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Mauer MJ, Perkins S,. . . **Karlan BY**, . . . et al: Tumorgrafts as *in vivo* surrogates for women with ovarian cancer. *Clin Cancer Res* 20(5):1288-1297; 2014. PMID: 24398046

232. Cohen JG, Tran AQ, Rimel BJ, Cass I, Walsh CS, **Karlan BY**, LI, AJ: Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival. *Gynecol Oncol* 132(3):556-559; 2014. PMID: 24423879
233. Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, Neuhausen SL, **Karlan B**, Kim Sing C, Huzarski T, Gronwald J, McCuaig J, Senter L, Tung N, Ghadirian P, Eisen A, Gilchrist D, Blum JL, Zakalik D, Pal T, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group: Timing of oral contraceptive use and the risk of breast cancer in *BRCA1* mutation carriers. *Breast Cancer Res Treat* 143(3):579-586; 2014. PMID: 24458845
234. Finch A, Lubinski J, Moller P, Maehle L, Singer C, Senter L, Rosen B, **Karlan B**..., Narod SA, The Hereditary Ovarian Cancer Clinical Study Group: Impact of oophorectomy on cancer incidence and mortality in women who carry a *BRCA1* or *BRCA2* mutation. *J Clin Oncol* 32(15):1547-1553; 2014. PMID: 24567435
235. Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PDP, Chenevix-Trench G, . . . **Karlan BY**, . . . et al: Variation in NF- $\kappa$ B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 23(7):1421-1427; 2014. PMID: 24740199
236. Osorio A, Milne RL, Kuchenbaecker K, Vaclova T, Pita G, Alonso R, Peterlongo P, . . . **Karlan BY**, . . . et al: DNA glycosylases involved in base excision repair may be associated with cancer risk in *BRCA1* and *BRCA2* mutation carriers. *PLoS Genet* 10(4)e1004256; 2014. PMID: 24698998
237. Wiedemeyer WR, Beach JA, **Karlan BY**: Reversing platinum resistance in high-grade serous ovarian carcinoma: Targeting *BRCA* and the homologous recombination system. *Front Oncol* 4:34; 2014. PMID: 24624361
238. **Karlan BY**, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N: Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated risk women. *Cancer Epidemiol Biomarkers Prev* 23(7):1383-1393; 2014. PMID: 24789859
239. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, . . . **Karlan BY**, . . . et al: Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunol Res* 2(4):332-340; 2014. PMID: 24764580
240. Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, C, . . . **Karlan B**, . . . et al: *ABCA* transporter gene expression and poor outcome in epithelial ovarian cancer. *J Natl Cancer Inst* 106(7):dju149; 2014. PMID: 14557074
241. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, . . . **Karlan BY**, . . . et al: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomized, multicenter, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol* 15(8):799-808; 2014. PMID: 24950985
242. Cass I, Walts AE, Barbuto D, Lester J, **Karlan B**: A cautious view of putative precursors of serous carcinomas in the fallopian tubes of *BRCA* mutation carriers. *Gynecol Oncol* 134(3):492-497; 2014. PMID: 25026639
243. Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, . . . **Karlan BY**, . . . et al.: Duration of tamoxifen use and the risk of contralateral breast cancer in *BRCA1* and *BRCA2* mutation carriers. *Breast Cancer Res Treat* 146(2):421-427; 2014. PMID: 24951267
244. Keleman LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, . . . **Karlan BY**, . . . et al.: Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. *Mol Nutr Food Res* 58(10):2023-2035; 2014. PMID: 25066213

245. Jin Y, Han B, Chen J, Wiedemeyer R, Orsulic S, Bose S, Zhang X, **Karlan BY**, Giuliano AE, Cui Y, Cui X: FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer. *Ann Surg Oncol* S758-S766; 2014. PMID: 25124473
246. Wang ET, Pisarska MD, Bresee C, Chen Y-DI, Lester J, Afshar Y, Alexander C, **Karlan BY**: *BRCA1* germline mutations may be associated with reduced ovarian reserve. *Fertil Steril* 102(6):1723-1728; 2014. PMID: 25256924
247. Gangi A, Cass I, Paik D, Barmparas G, **Karlan B**, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF: Breast cancer following ovarian cancer in *BRCA* mutation carriers. *JAMA Surg* 149(12):1306-1313; 2014. PMID: 25372568
248. Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Wiedemeyer WR, **Karlan BY**, Orsulic S: Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. *J Pathol Clin Res* 1(1):41-53; 2014. PMID: 27499892
249. Aspuria PJ, Lunt SY, Varembo L, Gergnes L, Gozo M, Beach JA, Salumbides B, Reue K, Wiedemeyer WR, Nielsen J, **Karlan BY**, Orsulic S: Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. *Cancer Metab* 2:21; 2014. PMID: 25671108
250. Kuchenbaecker KB, Neuhausen SL, Robson M...**Karlan BY**.....et al: Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in *BRCA1* and *BRCA2* mutation carriers. *Breast Cancer Res* 16(6):3416; 2014. PMID: 25919761
251. Spurdle AB, Couch FJ, Parsons MT, McGuffog L...**Karlan BY**...et al: Refined histopathological predictors of *BRCA1* and *BRCA2* mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* 16(6):3419; 2014. PMID: 25857409
252. Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, . . . **Karlan B**, . . . et al.: Factors influencing ovulation and the risk of ovarian cancer in *BRCA1* and *BRCA2* mutation carriers. *Int J Cancer* 137(5):1136-1146; 2015. PMID: 25482078
253. Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR,. . . **Karlan BY**, . . . et al: Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. *Oncotarget* 6(2):696-714; 2015. PMID: 25557169
254. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P,. . . **Karlan BY**, . . . et al.: Candidate genetic modifiers for breast and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 24(1):308-316; 2015. PMID: 25336561
255. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, . . . **Karlan BY**, . . . et al.: Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. *Gynecol Oncol* 136(3):542-548; 2015. PMID 25528498
256. Daly M, Dresher CW, Yates MS, Jeter JM, **Karlan BY**, Alberts DS, Lu K: Salpingectomy as a means to reduce ovarian cancer risk. *Cancer Prev Res* 8(5):342-348; 2015. PMID: 25586903
257. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K,. . . **Karlan BY**, . . . et al: Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet* 47(2):164-171; 2015. PMID: 25581431
258. Lojkin I, Rubinek T, Orsulic S, Schwarzmann O, **Karlan BY**, Bose S, Wolf I: Reduced expression and growth inhibitory activity of the aging suppressor *klotho* in epithelial ovarian cancer. *Cancer Lett* 362(2):149-157; 2015. PMID: 25827069



259. Coetzee SG, Shen HC, Hazellett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Krapkin R, Ramus SJ, Ovarian Cancer Association Consortium (**Karlan BY**), . . . et al: Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Hum Mol Genet* 24(13):3595-3607; 2015. PMID: 15804953
260. Candido-dos-Reis FJ, Song H, Good EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks, E, . . . **Karlan B**, . . . et al. : Germline mutation in *BRCA1* or *BRCA2* and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clin Cancer Res* 21(3):652-657; 2015. PMID: 25398451
261. Hussein YR, Weigelt B, Levine D, Schoolmeester JK, Balzer B, Liles G, **Karlan B**, Kobel M, Lee CH, Soslow RA: Clinicopathological analysis of endometrial carcinomas harboring somatic with *POLE* exonuclease domain mutations. *Mod Pathol* 28(4):505-514; 2015. PMID: 25394778
262. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, . . . **Karlan BY**, . . . et al: Assessing association between the *AURKA-HMMR-TPX2-TUBG1* functional module and breast cancer risk in *BRCA1/2* mutation carriers. *PLoS One* 10(4):e0120020 doi: 10.1371/journal.pone.0120020. eCollection 2015. PMID: 25830658
263. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, Antonenkova H, Australian Cancer Study; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium (**Karlan BY**): Genome-wide significant risk associations for mucinous ovarian carcinoma. *Nat Genet* 47(8):888-897; 2015. PMID: 26075790
264. Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, . . . **Karlan BY**, . . . et al: Risk factors for endometrial cancer among women with *BRCA1* or *BRCA2* mutation: a case control study. *Fam Cancer* 14(3):383-391; 2015. PMID: 25838159
265. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, . . . **Karlan BY**, . . . et al: Association of type and location of *BRCA1* and *BRCA2* mutations with risk of breast and ovarian cancer. *JAMA* 313(13):1347-1361; 2015. PMID: 25849179
266. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, . . . **Karlan BY**, . . . et al: An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in *BRCA2* mutation carriers. *Breast Cancer Res* 17(1):61; 2015. PMID: 25925750
267. Cheon DJ, Li AJ, Beach JA, Walts AE, Tran H, Lester J, **Karlan BY**, Orsulic S: ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. *Carcinogenesis* 36(7):739-747; 2015. PMID: 25926422
268. Rimel BJ, Lester J, Sabacan L, Park D, Bresee C, Dang C, **Karlan B**: A novel clinical trial recruitment strategy for women's cancer. *Gynecol Oncol* 138(2):445-448; 2015. PMID: 26001329
269. Zakhour M, LaBrant L, Rimel BJ, Walsh CS, Li AJ, **Karlan BY**, Cass I: Too much, too late: Aggressive measures and the timing of the end of life care discussions in women with gynecologic malignancies. *Gynecol Oncol* 138(2):383-387; 2015. PMID: 26049124
270. Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, Qu X, . . . **Karlan BY**, . . . et al: Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. *PLoS One* 10(6):e0128106; 2015. PMID: 26091520
271. Qu y, Han B, Yu Y, Yao W, Bose S, **Karlan BY**, Giuliano AE, Cui X: Evaluation of MCF10A as a reliable model for normal human mammary epithelial cells. *PLoS One* 10(7):e0131285; 2015. PMID: 26147507

272. Johnatty S, Tyrer JP, Kar SP, Beesley J, Lu, Y, Gao B, Fasching PA, . . . **Karlan BY**, . . . et al: Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes findings from the Ovarian Cancer Association Consortium. *Clin Cancer Res* 21(23):5264-5276; 2015. PMID: 26152742
273. Cohn DE, Havrilesky LJ, Osann K, Lipscomb J, Hsieh S, Walker JL, Wright AA, . . . **Karlan BY**, . . . et al: Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology Practice. *Gynecol Oncol* 138(3):712-716; 2015. PMID: 26177553
274. Novak M, Lester J, Karst AM, Parkash, Hirsch MS, Crum CP, **Karlan BY**, Drapkin R: Stathmin 1 and p16<sup>INK4A</sup> are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. *Gynecol Oncol* 139(1):104-111; 2015. PMID: 26206555
275. Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H, Antonenkova N, Chenevix-Trench G, . . . **Karlan BY**, . . . et al: Network-based integration of GWAS and gene expression identifies a *HOX*-centric network associated with serous ovarian cancer risk. *Cancer Epidemiol Biomarkers Prev.* 24(10):1574-1584; 2015. PMID: 26209509
276. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, . . . **Karlan BY**, . . . et al: Germline mutations in the *BRIP1*, *BARD1*, *PALB2*, and *NBN* genes in women with ovarian cancer. *J Natl Cancer Inst* 107(11); 2015. PMID: 26315354
277. Urban N, Hawley S, Janes H, **Karlan BY**, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CL, Anderson GL: Identifying postmenopausal women at elevated risk for epithelial ovarian cancer. *Gynecol Oncol* 139(2):253-260; 2015. PMID: 26343159
278. Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, **Karlan BY**, Orsulic S: Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. *Gynecol Oncol* 139(3):394-400; 2015. PMID: 26348314
279. Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J, . . . **Karlan BY**, . . . et al: *Cis*-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nat Commun* 6:8234; 2015. PMID: 26391404
280. Amankwah EK, Lin HW, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, . . . **Karlan BY**, . . . et al: Epithelial-mesenchymal transition (EMT) gene variants and epithelial ovarian cancer (EOC) risk. *Genet Epidemiol* 39(8):689-697; 2015. PMID: 26399219
281. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, Li Q, . . . **Karlan BY**, . . . et al: Common variants at the *CHEK2* gene locus and risk of epithelial ovarian cancer. *Carcinogenesis* 36(11):1341-1353; 2015. PMID: 26424751
282. Semple J, Metcalfe KA, Lubinski J, Huzarski T, Gronwald J, Armel S, Lynch HT, **Karlan B**, Foulkes W, Singer CF, Neuhausen SL, Eng C, Iqbal J, Narod SA, Hereditary Breast Cancer Clinical Study Group: Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in *BRCA1* and *BRCA2* mutation carriers? *Breast Cancer Res Treat* 154(1):163-169; 2015. PMID: 26467043
283. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, . . . **Karlan BY**, . . . et al: Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. *Nat Rev Cancer* 15(11):668-679; 2015. PMID: 26493647
284. Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Chen Z, . . . **Karlan BY**, . . . et al.: Common genetic variation in circadian rhythm genes and risk of epithelial ovarian cancer (EOC). *J Genet Genome Res* 2(2)1-23; 2015. PMID: 26807442

285. Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL, Ovarian Cancer Association Consortium (**Karlan BY**): Evidence of a genetic link between endometriosis and ovarian cancer. *Fertil Steril* 105(1):35-43.e1-10; 2016. PMID: 26477498
286. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, . . . **Karlan BY**, . . . et al: *BRCA2* polymorphic stop codon K3326X and the risk of breast, prostate and ovarian cancers. *J Natl Cancer Inst* 108(2):pii:djv347; 2016. PMID: 26586665
287. Dao F, Schluppe DF, Tseng BA, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, **Karlan BY**, Sood AK, Levine DA: Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. *Gynecol Oncol* 141(2):260-263; 2106. PMID: 26968641
288. Levine DA, **Karlan BY**, Strauss FJ 3<sup>rd</sup>, et al: Evolving approaches in research and care for ovarian cancers: A report from the National Academies of Sciences, Engineering, and Medicine. *JAMA* 315(18):1943-1944; 2016. PMID: 26934631
289. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, . . . **Karlan BY**, . . . et al.: Breast cancer risk variants at 6q25 display different phenotype associations and regulate *ESR1*, *RMND1* and *CCDC170*. *Nat Genet* 48(4):374-386; 2016. PMID: 26928228
290. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, **Karlan BY**, Mitchell G, et al.: Male breast cancer in *BRCA1* and *BRCA2* mutation carriers: pathology data from the consortium of investigators of modifiers of *BRCA1/2*. *Breast Cancer Res* 18(1):15; 2016. PMID: 26857456
291. French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, . . . **Karlan B**, . . . et al.: Germline polymorphisms in an enhancer of *PSIP1* are associated with progression-free survival in epithelial ovarian cancer. *Oncotarget* 7(6):6353-6368; 2016. PMID: 26840454
292. Pharoah PD, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K, . . . **Karlan BY**, . . . et al.: *PPM1D* mosaic truncating variants in ovarian cases may be treatment-related somatic mutations. *J Natl Cancer Inst* 108(3). pii:djv347; 2016. PMID: 26823519
293. Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, . . . **Karlan B**, . . . et al.: Hormone replacement therapy after menopause and risk of breast cancer in *BRCA1* mutation carriers: A case-control study. *Breast Cancer Res Treat* 155(2):365-373; 2016. PMID: 26780555
294. Winham SJ, Pirie A, Chen YA, Larson MC, Fogarty ZC, Earp MA, Anton-Culver H, . . . **Karlan BY**, . . . et al.: Investigation of exomic variants associated with overall survival in ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 25(3):446-454; 2016. PMID: 26747452
295. Beach JA, Aspuria PJ, Cheon DJ, Lawrenson K, Agadjanian H, Walsh CS, **Karlan BY**, Orsulic S: Sphingosine kinase 1 is required for TGF- $\beta$  mediated fibroblast-to-myofibroblast differentiation in ovarian cancer. *Oncotarget* 7(4):4167-4182; 2016. PMID: 26716409
296. Vogel TJ, Jeon C, **Karlan B**, Walsh C: Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. *Gynecol Oncol* 140(2):285-288; 2016. PMID: 26691221
297. Wang Y, Bernhardt AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, . . . **Karlan B**, . . . et al: The *BRCA1*- $\Delta$ 11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. *Cancer Res* 76(9):2778-2790; 2016. PMID: 27197267

298. Alvarez RD, **Karlan BY**, Strauss JF: "Ovarian cancers: Evolving paradigms in research and care" Report from the Institute of Medicine. *Gynecol Oncol* 141(3):413-415; 2016. PMID: 27138456
299. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, . . . **Karlan BY**, . . . et al: Identification of four novel susceptibility loci for estrogen receptor negative breast cancer. *Nat Commun* April 7:11375; 2016. PMID: 27117709
300. Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, . . . **Karlan BY**, . . . et al: An international survey of surveillance schemes for unaffected *BRCA1* and *BRCA2* mutation carriers. *Breast Cancer Res Treat* 157(2):319-327; 2016. PMID: 27117159
301. Hodeib M, Cohen JG, Mehta S, Rimel BJ, Walsh CS, LI AJ, **Karlan BY**, Cass I: Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN. *Gynecol Oncol* 141(3):507-510; 2016. PMID: 27032375
302. Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L, Tung NM, Manoukian S, Phelan CM, Sun P, Narod SA, Hereditary Breast Cancer Research Group (**Karlan BY**): The incidence of leukaemia in women with *BRCA1* and *BRCA2* mutations: an international prospective cohort study. *Br J Cancer* 114(10):1160-1164; 2016. PMID: 26986251
303. Ovarian Cancer Association Consortium (**Karlan BY**), Breast Cancer Association Consortium and Consortium of Modifiers of *BRCA1* and *BRCA2*, et al: No clinical utility of *KRAS* variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol*, 141(2):386-401; 2016. PMID: 25940428
304. Gronwald J, Glass K, Rosen B, **Karlan B**, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J, Hereditary Breast Cancer Clinical Study Group: Treatment of infertility does not increase the risk of ovarian cancer among women with a *BRCA1* or *BRCA2* mutation. *Fertil Steril* 105(3):781-785; 2016. PMID: 26698676
305. Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghossaini M, . . . **Karlan BY**, . . . et al: Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Res* 18(1):64; 2016. PMID: 27459855
306. Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dork T, Hillemanns P, . . . **Karlan BY**, . . . et al: Assessment of variation in immunosuppressive pathway genes reveals *TGFBR2* to be associated with risk of clear cell ovarian cancer. *Oncotarget* 7(43):69097-69110; 2016. PMID: 27533245
307. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, . . . **Karlan BY**, . . . et al: Fine-Scale mapping at 9p22.2 identifies candidate causal variants that modify ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers. *PLoS One* 11(7):e01588001; 2016. PMID: 27463617
308. Kanska J, Zakhour M, Taylor-Harding B, **Karlan BY**, Wiedemeyer WR: Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. *Gynecol Oncol* 143(1):152-158; 2016. PMID: 27461360
309. Kar SP, Beesley J, Amin AL, Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, . . . **Karlan BY**, . . . et al: Genome-Wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. *Cancer Discov* 6(9):1052-1067; 2016. PMID: 27432226
310. Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearch CL, Zheng W, Painter JN, . . . Ovarian Cancer Association Consortium (**Karlan BY**), . . . et al: Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *Int J Epidemiol* 45(3):884-895; 2016. PMID: 27401727

311. Permuth JB, Pirie A, Ann Chen Y, Lin HY, Reid BM, Chen Z, Monteiro A, . . . Ovarian Cancer Association Consortium (**Karlan BY**), et al: Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. *Hum Mol Genet* 25(16):3600-3612; 2016. PMID: 27378695
312. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, . . . **Karlan BY**, . . . et al: Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. *Gynecol Oncol*, 143(1):27-34; 2016. PMID: 27546885
313. Southey MC, Goldgar DE, Wingvist R, Pylkas K, Couch F, Tischkowitz M, Foulkes WD, . . . **Karlan BY**, . . . et al: *PALB2*, *CHEK2* and *ATM* rare variants and cancer risk: data from COGS. *J Med Genet* 53(12):800-811; 2016. PMID: 27595995
314. Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, **Karlan BY**, et al: Bilateral oophorectomy and breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* 109(1); 2016. PMID: 27601060
315. Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, Beesley J, . . . **Karlan B**, . . . et al: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun* 7:12675; 2016. PMID: 27601076
316. **Karlan BY**, Alvarez RD, Strauss JF: Evolving paradigms in research and care in ovarian cancers. *Obstet Gynecol* 128(4):771-774; 2016. PMID: 27607869
317. Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, **Karlan BY**, Orsulic S: A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for prioritization of therapeutic targets. *Cancer Lett* 382(2):203-214; 2016. PMID: 27609069
318. Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, **Karlan BY**, Cass I: Occult and subsequent cancer incidence following risk-reducing surgery in *BRCA* mutation carriers. *Gynecol Oncol* 143(2):231-235; 2016. PMID: 27623252
319. Gozo MC, Jia D, Aspuria PJ, Cheon DJ, Miura N, Walts AE, **Karlan BY**, Orsulic S: FOXC2 augments tumor propagation metastasis in osteosarcoma. *Oncotarget* 7(42):68792-68802; 2016. PMID: 27634875
320. Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, . . . **Karlan BY**, . . . et al: Inheritance of deleterious mutations at both *BRCA1* and *BRCA2* in an international sample of 32,295 women. *Breast Cancer Res* 18(1):112; 2016. PMID: 27836010
321. Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z; AOCS Study Group, . . . **Karlan B**, . . . et al: Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget* 7(45):72381-72394; 2016. PMID: 27911851
322. Hamdi Y, Soucy P, Kuchenbaecker KB, Pastinen T, Droit A, Lemacon A, Adlard J, . . . **Karlan BY**, . . . et al: Association of breast cancer risk in *BRCA1* and *BRCA2* mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Res Treat* 161(1):117-134; 2017. PMID: 27796716
323. Kar SP, Adler E, Tyrer J, Hazelett D, Anton-Culver H, Bandera EV, Beckmann MW, . . . **Karlan BY**, . . . et al: Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *Br J Cancer* 116(4):524-535; 2017. PMID: 28103614

324. Suckeston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, . . . **Karlan BY**, . . . et al: No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. *Cancer Epidemiol Biomarkers Prev* 26(3):420-424; 2017. PMID: 27677730
325. Conley A, Minciocchi VR, Lee DH, Knudsen BS, **Karlan BY**, Dittrigno L, Viglietto G, et al: High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients. *RNA Biol* 14(3):305-316; 2017. PMID: 27858503
326. Cancer Genome Atlas Research Network (**Karlan BY**), et al: Integrated genomic and molecular characterization of cervical cancer. *Nature* 543(7645):378-384; Mar 2017. PMID: 28112728
327. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, . . . **Karlan BY**, . . . et al: Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet* 49(5):680-691; Mar 2017. PMID: 28346442
328. Dicks E, Song H, Ramus SJ, Van Oudenhove E, Tyrer JP, Intermaggio MP, Kar S, . . . **Karlan BY**, . . . et al: Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. *Oncotarget* 8(31):50930-50940; March 2017. PMID: 28881617
329. Kanska J, Aspuria PP, Taylor-Harding B, Spurka L, Funari V, Orsulic S, **Karlan BY**, Wiedemeyer WR: Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. *Oncotarget* 8(16):26200-26220; Apr 2017. PMID: 28412735
330. Babic A, Cramer DW, Kelemen LE, Kobel M, Steed H, Webb PM, Johnatty SE, . . . **Karlan BY**, . . . et al: Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. *Cancer Causes Control* 28(5):459-468; May 2017. PMID: 28050675
331. Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, . . . **Karlan BY**, . . . et al: History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. *Cancer Causes Control* 28(5):469-486; May 2017. PMID: 28293802
332. McGee J, Giannakeas V, **Karlan B**, Lubinski J, Gronwald J, Rosen B, McLaughlin J, et al: Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? *Gynecol Oncol* 145(2):346-351; May 2017. PMID: 28314588
333. Cohen JG, Prendergast E, Geddings JE, Walts AE, Agadjanian H, Hisada Y, **Karlan BY**, Mackman N, Walsh CS: Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. *Gynecol Oncol* 146(1):146-152; Jul 2017. PMID: 28501328
334. Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, **Karlan BY**, Levine DA, Sood AK. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. *Gynecol Oncol* 146(1):101-108; 2017Jul. PMID: 28527672
335. Haemmerle M, Taylor, ML, Gurschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS,....**Karlan BY**...et al: Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. *Nat Commun*; 8(1):310, 1-15; 2017 Aug. PMID: 28827520
336. Glubb DM, Johnatty SE, Quinn MCJ, O'Mara TA, Tyrer JP, Gao B, Fasching PA Beckmann MW, Lambrechts D, Vergote I,....**Karlan BY**,...et al: Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. *Oncotarget* 8(39):64670-64684; Sept 2017. PMID: 29029385

337. Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor P, Etter JL, Cramer DW, Diergaarde B, Doherty JA, ....**Karlan BY**, ...et al: History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. *Br J Cancer* 117(7):1063-1069; 2017 Sep. PMID: 28817835
338. Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender JB, Segal B, Odunsi K, Mayor P, Diergaarde B, Zsiros E,....**Karlan BY**...et al: History of comorbidities and survival of ovarian cancer patients, results from the Ovarian Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 26(9):1470-1473; 2017 Sep. PMID: 28864456
339. Yucer N, Holzapfel M, Jenkins Vogel T, Lenaeus L, Ornelas L, Laury A, Sareen D, Barrett R, **Karlan BY**, Svendsen CN: Directed differentiation of human induced pluripotent stem cells into fallopian tube epithelium. *Sci Rep* 7(1):10471, 1-9; 2017 Sep. PMID: 28878359
340. Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A,....**Karlan BY**...et al: Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. *JAMA Oncol* e173290, doi: 10.1001/jamaoncol.2017.3290; 2017 Dec. (Epub ahead of print) PMID: 29049607
341. Jones MR, Kamara D, **Karlan BY**, Pharoah PDP, Gayther SA: Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. *Gynecol Oncol* 147(3):705-713; 2017 Dec. PMID: 29054568
342. Cancer Genome Atlas Research Network (**Karlan BY**): Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. *Cell* 171(4):950-965.e28; 2017. PMID: 29100075
343. Hodeib M, Ogrodzinski MP, Vergnes L, Reue K, **Karlan BY**, Lunt SY, Aspuria PP: Metformin induces distinct bioenergetic and metabolic profiles in sensitive versus resistant high grade serous ovarian cancer and normal fallopian tube secretory epithelial cells. *Oncotarget*, 9(3):4044-4060; 2017 Dec 23 (eCollection 2018 Jan 9). PMID: 29423103
344. Sims JD, Taguiam JM, Alonso-Valenteen F, Markman J, Agadhanian H, Chu D, Lubow J, Abrol R, Srinivas D, Jain A, Han B, Qu Y, Mirzadehgan P, Hwang JY, Rentsendorj A, Chung A, Lester J, **Karlan BY**, Gray HB, Gross Z, Giuliano A, Cui X, Medina-Kauwe LK: Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. *J Control Release*, 271:127-138; 2018 Feb 10. (Epub ahead of print) PMID: 29288681
345. Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Toloczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R....**Karlan BY**...et al: MyD88 and TLR4 Expression in Epithelial Ovarian Cancer, *Mayo Clin Proc.* 93(3):307-320; 2018 Mar. PMID: 29502561
346. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E....**Karlan BY**....et al: Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat.* doi:10.1002.humu.23406; 2018 Mar 12 (Epub ahead of print) PMID: 29446198
347. Kim SJ, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, **Karlan BY**....et al: Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Int J Epidemiol.* doi:10.1093/ije/dyy039; 2018 Mar 13 (Epub ahead of print) PMID: 29547931
348. Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W....**Karlan BY**....et al: Adult height is associated with increased risk of ovarian cancer: a Mendelian randomization study. *Br J Cancer.* doi:10.038/s41416-018-0011-3; 2018 Apr (Epub ahead of print) PMID: 29555990

349. Saini U, Suarez AA, Naidu S, Wallbiollich JJ, Bixel K, Wanner R, Bice J, Kladney RD, Lester J, **Karlan BY**, Goodfellow PJ, Cohn DE, Selvendiran K: STAT3/PIAS3 levels serve as “early signature” genes in the development of high-grade serous carcinoma from the fallopian tube. *Cancer Res* doi:10.1158/0008-5472; 2018 Apr 1 (Epub ahead of print). PMID: 29339537
350. Metcalfe KA, Lubinski J, Gronwald J, Huzarski T, McCuaig J, Lynch HT, **Karlan BY**, Foulkes WD, et al: The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer. *Clin Genet*. 93(5):1063-1068; 2018 May. PMID: 29206279
351. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong Am, Olah E, Olopado OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ.....**Karlan BY**....et al: Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat*. 39(5):593-620; 2018 May. PMID: 29446198
352. Von Gruenigen VE, **Karlan BY**: Sexual harassment in the workplace: Its impact on gynecologic oncology and women’s health. *Gynecol Oncol*. 149(2):227-229; 2018 May. PMID: 29526475
353. Prendergast EN, de Souza Fonseca MA, Dezem FS, Lester J, **Karlan BY**, Noushmehr H, Lin X, Lawrenson K: Optimizing exosomal RNA isolation for RNA-Seq analyses of archival sera specimens. *PLoS One*. 13(5):e0196913; 2018 May 8; eCollection 2018. PMID: 29738525
354. Wield AM, Walsh CS, Rimel BJ, Cass I, **Karlan BY**, Li AJ: Aspirin use correlates with survival in women with clear cell ovarian cancer. *Gynecol Oncol Rep*. 25:78-81; 2018 June; eCollection 2018 Aug. PMID: 29922710.
355. Kotsopoulos J, Gronwald J, **Karlan BY**, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group: Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. *Gynecol Oncol*. 150(1):85-91; 2018 July. PMID: 29793803
356. Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Aben KKH, Anton-Culver H, Antonenkova N...**Karlan BY**...et al: Variants in genes encoding small GUPases and association with epithelial ovarian cancer susceptibility. *PLoS One*. 13(7):e0197561; 2018 Jul 6; eCollection 2018. PMID: 29979793
357. Kotsopoulos J, Gronwald J, **Karlan BY**, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L Eisen A, Singer CF....et al: Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. *JAMA Oncol*.4(8):1059-1065; 2018 Aug 1. PMID: 29710224
358. Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G.....**Karlan BY**....et al: rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma Carcinoma of Mucinous Histology. *Int J Mol Sci*. 19(9). pii: E2473; 2018 Aug 21. PMID: 30134598
359. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JMIm HK, Chen YA, Permuth JB, Reid BM Teer JK.....**Karlan BY**....et al: A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. 78(18):5419-5430; 2018 Sep 15. PMID: 30054336
360. Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, Kommoss S....**Karlan BY**....et al: Association of p16 Expression with Prognosis Varies Across Carcinoma Histotypes: An Ovarian Tumor Tissue Analysis Consortium Study. *J Pathol Clin Res*. 4(4):250-261; 2018 Oct. PMID: 30062862



361. Qian F, Wang S, Mitchell J, McGuffog, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K...**Karlan BY**...et al: Height and body mass index as modifiers of breast cancer risk in BRCA ½ mutation carriers: A Mendelian randomization study. *J Natl Cancer Inst.* 2018 Oct 12. PMID: 30312457
362. Chang H, Rimel BJ, Li AJ, Cass I, **Karlan BY**, Walsh C: Ultrasound guided transversus abdominis plane (TAP) block utilization in multimodal pain management after open gynecological surgery. *Gynecol Oncol Rep.* 26:75-77; 2018 Oct 15; eCollection 2018 Nov. PMID: 30364775
363. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlanta Research Network (**Karlan BY**), Camargo F, Liang H: Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Rep.* 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001. PMID: 30380420
364. Andersen MR, **Karlan BY**, Drescher CW, Paley P, Hawley S, Palomares M, Daly MB, Urban N: False-positive Screening Events and Worry Influence Decisions About Surgery Among High-risk Women. *Health Psychol.* Doi: 10, 1037/hea0000647; 2018 Nov 15 (Epub ahead of print). PMID: 304312092
365. Gill NK, Ly C, Nyberg KD, Lee L, Qi D, Tofig B, Reis-Sobreiro M, Dorigo O, Rao J, Wiedemeyer R, **Karlan BY**, Lawrenson K, Freeman MR, Damoiseaux R, Rowat AC: A scalable filtration method for high throughput screening based on cell deformability. *Lab Chip.* 2019 Jan 15; 19(2):343-357. Doi 10.1039/c8lc00922h. PMID: 30566156
366. Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q,...**Karlan BY**...et al: Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Res.* 2019 Feb1; 79(3):505-517. doi: 10.1158/0008-5472.CAN-18-2726. Epub 2018 Dec 17. PMID: 30559148
367. Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, Song M, Hirsch MS, Lester J, Parkash V, **Karlan BY**, Oren M, Hoon DS, Drapkin R.: Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways that Facilitate progression of Ovarian Cancer *Cancer Res.* 2019 Feb 15;79(4):760-772. doi: 10.1158/0008-5472.CAN-18-2297. Epub 2018 Dec 18. PMID: 30563893
368. Jiang X, Finucane HK, Schumacher FR, Schmit SL...**Karlan BY**...et al: Shared heritability and functional enrichment across six solid cancers. *Nat Commun.* 2019 Jan 25; 10(1):431. Doi: 10.1038/s41467-018-08054-4 PMID: 30683880
369. Orsulic S, **Karlan BY**.: Can molecular subtyping be used to triage women with advanced ovarian cancer to primary debulking surgery or neoadjuvant chemotherapy? *Gynecolo Oncol.* 2019 Feb; 152(2):221-222. Doi: 10.1016/j.ygyno.2019.01.005 PMID:30704616
370. Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L...**Karlan BY**...Narod SA, Hereditary Breast Cancer Clinical Study Group: Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.* 2019 Feb 12. Doi:10.11007/s10549-019-05162-7. PMID: 30756284
371. Lawrenson K, Song F, Hazelett DJ, Kar SP....**Karlan BY**...et al: Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. *Gynecol Oncol.* 2019 Mar 19 pii: S0090-8258(19)30133-7. doi: 10.1016/j.ygyno.2019.02.23. PMID: 30898391

372. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, . . . **Karlan B**, . . . et al: International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. *Br J Cancer*. 2019 Apr 11. Doi: 10.1038/s41416-019-0446-1. [Epub ahead of print].
373. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomaki K, Andrulis IL, Anton-Culver H. Arason A, . . . **Karlan BY**, . . . et al: Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nat Commun*. 2019 Apr 15;10(1):1741. Doi: 10.1038/s41467-018-08053-5. PMID: 30988301
374. Grant DJ, Manichaikul A, Alberg AJ, Bandera EV, Harnholtz-Sloan J. Bondy M. Cote ML, . . . **Karlan BY**, . . . et al: Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Med*. 2019 Apr 18. doi: 10.1002/cam4.1996 [Epub ahead of print]. PMID: 31001917
375. Gusev A, Lawrenson K, Lin X, Lyra PC Jr, Kar S, Vavra KC, Segato F, . . . **Karlan BY**, . . . et al: A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants. *Nat Genet*. 2019 May; 51(5):815-823. doi: 10.1038/s41588-019-0395-x. Epub 2019 May 1. PMID: 31043753
376. Lin S, Spindler TJ, de Souza Fonseca MA, Corona RI, Seo J-H, Dezem FS, Li L,. . . **Karlan BY**,. . . et al: Super-Enhancer-Associated LncRNA UCA1 interacts directly with AMOT to activate YAP target genes in Epithelial Ovarian Cancer. *IScience*. **Need identifying numbers and page numbers.**

**B. Research Papers – [Peer Reviewed – In Press]**

None

**C. Research Papers – [Peer Reviewed – Submitted]**

None

**D. Articles and Reviews**

1. **Karlan BY**, Byfield JE, Lagasse LD: Multimodality therapy for gyn malignancies. *Contemporary OB/GYN* 33:27-42, 1989.
2. **Karlan BY**, Lagasse LD: Conservative management of vulvar cancer. *Contemporary OB/GYN* 35:27-35, 1990.
3. **Karlan BY**, Krakow D: Genetic aspects of ovarian cancer: *Current Opinion Obstetrics and Gynecology*, 6(1):105-110, 1994.
4. Cirisano FD, **Karlan BY**: Role of HER-2/neu in gynecologic malignancies. *Contemporary OG/GYN* 41:49-72, 1996.
5. Bristow RE, **Karlan BY**: The risk of ovarian cancer after treatment for infertility. *Current Opinion Obstetrics and Gynecology* 8(1):32-37, 1996.
6. Bristow RE, **Karlan BY**: Interval surgical cytoreduction in advanced epithelial ovarian cancer. *Postgraduate Obstetrics & Gynecology* 16:1-7, 1996.

7. Crvenkovic G, **Karlan BY**, Platt LD: Current role of ultrasound in ovarian cancer screening. Clin Obstet Gynecol, 39(1):259-267, 1996.
8. Elkas JC, **Karlan BY**: The role of reassessment laparoscopy in managing of ovarian cancer. Contemporary OB/GYN 43:101-111, 1998.
9. Chen LM, **Karlan BY**: Early detection and risk reduction for familial gynecologic cancers. Clin Obstet Gynecol, 41(1):200-214, 1998.
10. Kirk JH, **Karlan BY**, Cane P, Gregory K: Hysterectomy in a decade of change: more than a weighty matter. Primary Care Update Ob/Gyns 5(4):203-204, 1998.
11. Cass I, Baldwin RL, **Karlan BY**: Molecular advances in gynecologic oncology. Current Opinion Oncology 11(5):394-400, 1999.
12. Li AJ, **Karlan BY**: Breast cancer prevention. OB/GYN Special Edition, 2000.
13. **Karlan BY**: Ovarian cancer treatment options and symptom management. COPING, 50-51, May/June 2000.
14. Chen LM, **Karlan BY**: Recurrent ovarian carcinoma: Is there a place for surgery? Semin Surg Oncol 19(1):62-68, 2000.
15. Li AJ, **Karlan BY**: Genetic factors in ovarian carcinoma. Curr Oncol Rep, 3(1):27-32, 2001.
16. Li AJ, Cass I, **Karlan BY**: *BRCA1* and *BRCA2*: Genetic testing and intervention strategies. Contemporary OB/GYN, 46:83-95, 2001.
17. Wang J, Li AJ, **Karlan BY**: Chemotherapy in epithelial ovarian cancer. Current Women's Health Reports 2(1):20-26, 2002.
18. Wang J, **Karlan BY**: Genetic testing in the gynecology practice. Women's Health, Gynecology Edition 3:153-160, 2003.
19. Wang J, **Karlan BY**: Management of patients who carry a cancer gene. Women's Health, Gynecology Edition 3:209-214, 2003.
20. Li AJ, **Karlan BY**: Surgical advances in the treatment of ovarian cancer. Hematology-Oncology Clinics of North America 17(4):945-956, 2003.
21. Urban N, McIntosh MW, Andersen M, **Karlan BY**: Ovarian cancer screening. Hematology-Oncology Clinics of North America 17(4):989-1005, 2003.
22. Walsh CS, **Karlan BY**: Contemporary progress in ovarian cancer screening. Curr Oncol Rep 9(6):485-493, 2007.
23. Coleman R, **Karlan BY**: Ovarian Cancer: Updates from the 16th International Meeting of the European Society of Gynaecological Oncology. European Society of Gynaecological Oncology Newsletter, 2009.
24. ACOG Committee on Practice Bulletins on Genetics and the Society of Gynecologic Oncologists with the editorial assistance of **Beth Karlan, MD**, Andrew Berchuck, MD and David Mutch, MD: ACOG Practice Bulletin: Hereditary Breast and Ovarian Cancer Syndrome, 113(4):957-966; 2009. PMID: 19305347
25. **Karlan BY**: Debate: Routine screening for patients at high risk for ovarian cancer. Pro: Patients at high risk for ovarian cancer should undergo routine screening. Clin Ovarian Cancer 2:83-85, 2009.

26. ACOG Committee on Practice Bulletins on Genetics and the Society of Gynecologic Oncologists with the editorial assistance of **Beth Karlan, MD**, Andrew Berchuck, MD and David Mutch, MD: ACOG Practice Bulletin: Hereditary Breast and Ovarian Cancer Syndrome, *Gynecol Oncol*, 113:6-11; 2009. PMID: 19309638
27. **Karlan BY**, Lu KH, Mutch DG: Clinical implications of genetic testing for cancer susceptibility. *ACOG Update* (8):35, 2010.
28. Drescher CW, **Karlan BY**: Progress towards ovarian cancer early detection: Strategies, guidelines and clinical trials. *The Female Patient*, 35(4):22-25, 2010.
29. Rustin G, **Karlan BY**, Markman M: CA-125: To monitor or not to monitor? [www.medscape.com](http://www.medscape.com), Posted: March 08, 2012.
30. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, **Karlan Y**: Ovarian cancer. *Nat Rev Dis Primers* 2:16061; 2016. PMID: 27558151

## E. Chapters

1. Ashman RF, **Karlan BY**: From crosslinking to capping: order of intermediate events. In: *B-Lymphocytes in the Immune Response: Functional, Developmental and Interactive Properties*. Klinman, Mosier, Scher and Vitetta (eds). Elsevier, Holland, pp 163-167, 1981.
2. Farias-Eisner R, Lagasse LD, **Karlan BY**: Diagnosis and management of injuries to the genitourinary and gastrointestinal tracts. In: *Gynecologic Emergencies*. Karlan BY, Surrey E (eds). W.B. Saunders Co., pp 839-848, 1992.
3. **Karlan BY**, Lagasse LD: Surgical staging. In: *Surgical Gynecologic Oncology*, E Burghardt, MJ Webb (eds). Thieme Verlag, pp 241, 365, 459, 1993.
4. McGonigle KF, Lagasse LD, **Karlan BY**: Ovarian, uterine, and cervical cancer in the elderly woman. In: *Clinics In Geriatric Medicine*, FE Kaiser (ed). W. B. Saunders Co., 9(1), pp 115-130, 1993.
5. Sarti DA, **Karlan BY**, Platt LD: The role of ultrasound in ovarian cancer screening. In: *Ultrasound Categorical Course Syllabus*, Stephanie R. Wilson, M.D. FRCP(C) (ed). American Roentgen Ray Society, 93rd Annual Meeting, pp 21-26, 1993.
6. Crvenkovic G, Smrt C, Platt LD, **Karlan BY**: Strategies for ovarian cancer screening. In: *Doppler Ultrasound in Obstetrics and Gynecology*, Joshua A. Copel, Kathryn L. Reen (eds). Raven Press, Ltd., New York, NY, pp 55-60, 1994.
7. Shapter A, Berchuck A, **Karlan BY**: Hereditary Aspects of Female Cancers. In: *Biology of Female Cancers*. A Berchuck, Miller, Langdon (eds). CRC Press, Inc., New York, NY, pp 285-295, 1997.
8. Baldwin RL, Yamada SD, Bristow RE, Chen LM, **Karlan BY**: Ovarian epithelial growth regulation. In: *Ovarian Cancer 5*. Frank Sharp, Tony Blackett, Jonathan Berek, Robert Bast (ed). ISIS Medical Media, Oxford, England, pp 99-107, 1998.
9. Nielsen LL, Pegram M, **Karlan B**, Elkas J, Horowitz JA: Opportunities for p53 tumor suppressor gene therapy in ovarian and other peritoneal cancers. In: *Adenoviral Vectors for Gene Therapy*, S Prem (ed). Landes Bioscience, Chapter 32; pp 293-301, 1999.

10. Bristow RE, **Karlan BY**: Disorders of the uterine cervix. In: *Danforth's Obstetrics and Gynecology*, 8<sup>th</sup> Edition. James R. Scott, Philip J. DiSaia (ed). Lippincott-Raven Publishers. pp 805-835, 1999.
11. Elkas JC, **Karlan BY**: Vulvar cancer. In: *Gynecology for the Primary Care Physician, 1st Edition*, Chapter 24. Stovall TG, Ling FW (eds). Current Medicine Group, Philadelphia, PA. pp 189-194, 1999.
12. Elkas JC, **Karlan BY**: Vaginal cancer. In: *Gynecology for the Primary Care Physician, 1st Edition*, Chapter 25. Stovall TG, Ling FW (eds). Current Medicine Group, Philadelphia, PA. pp 195-198, 1999.
13. Pegram MD, Konecny G, Buller R, Runnebaum I, Slamon DJ, Nielsen LL, Horowitz J, **Karlan BY**: Preclinical and Phase I clinical studies of combinations of chemotherapy with recombinant adenovirus containing the full-length, human *p53* tumor suppressor gene cDNA for *p53*-mutant ovarian cancer. *Ovarian Cancer 6*, Jacobs IJ, Shepherd JH, Oram DH, Blackett AD, Luesley DM, Berchuck A, Hudson CN (eds). Oxford University Press, New York. 2002.
14. Scheuner M, **Karlan BY**: Reproductive organ cancers. In: *The Genetic Basis of Common Diseases, Second Edition*. Richard A King, Jerome I. Rotter, Arno G. Motulsky (eds), Oxford University Press. 2002.
15. Chen LM, **Karlan BY**: Ovarian cancer risk and prophylactic oophorectomy. In: *Operative Gynecology, Second Edition*. David M. Gershenson, Alan H. DeCherney, Stephen L. Curry, Linda Brubaker (eds). W.B. Saunders Company. 2002.
16. Platt LD, **Karlan BY**, Greene N, Walla CA: Screening for ovarian cancer. In: *Contemporary Therapy in Obstetrics and Gynecology Issues and Controversies*. Chapter 79, page 399-403. Scott Ransom, Mitchell P. Dombrowski, Mark Evans, Kenneth A. Ginsburg (eds). W.B. Saunders Company, Philadelphia, PA, and Harcourt Health Sciences CO, 2002.
17. Cass I, Baldwin RL, **Karlan BY**: Molecular biology of gynecologic malignancies. In: *Tumors of the Pelvis*. B.Ch. Golematis, K.A. Dimopoulos (eds). J Wiley & Sons, 2002.
18. Urban N, McIntosh MW, Clarke L, Jacobs IJ, **Karlan B**, Anderson G, Drescher C: Socio-economics of ovarian cancer screening, in *Ovarian Cancer 6*, Jacobs IJ, Shepherd JH, Oram DH, Blackett AD, Luesley DM, Berchuck A, Hudson CN (eds). Oxford University Press, New York. 199-208, 2002.
19. Li AJ, **Karlan BY**: Gestational trophoblastic neoplasms. In: *Danforth's Obstetrics and Gynecology, 9<sup>th</sup> Edition*, Chapter 57, pages 1019-1030. James Scott, Ronald S. Gibbs, Beth Karlan, Arthur Haney (eds). Lippincott Williams & Wilkins, 2003.
20. Cass I, **Karlan BY**: Neoplasms of the ovary and fallopian tube. In: *Danforth's Obstetrics and Gynecology, 9<sup>th</sup> Edition*, Chapter 55, pages 971-1006. James Scott, Ronald S. Gibbs, Beth Karlan, Arthur Haney (eds). Lippincott Williams & Wilkins, 2003.
21. **Karlan BY**, Markman MA, Eifel PA: Ovarian cancer, peritoneal carcinoma, and fallopian tube carcinoma (Chapter 32.4). In: *Cancer: Principles & Practice of Oncology, 7th Edition*. V.T. DeVita, S. Hellman, Rosenberg SA (eds). Lippincott Williams & Wilkins, 2005.
22. Cass I, **Karlan BY**: Second-look Surgery. In: *Surgery for Ovarian Cancer Principles and Practice*, Chapter 10. Bristow RE and Karlan BY (eds). Taylor & Francis Publishers, United Kingdom, 2006.
23. Pavelka J, Li AJ, **Karlan BY**: Hereditary Ovarian Cancer – Assessing Risk and Prevention Strategies. In: *Obstetric and Gynecology Clinics of North America*, Volume 34. Carolyn Y. Muller (ed). W. B. Saunders Company, 2007.

24. Pavelka JC, **Karlan BY**: Vulvar cancer. In: *Gynecology for the Primary Care Physician*, 2nd Edition, Chapter 25. Stovall TG, Ling FW, Nikki BZ, Chuang AW, Tillmanns TT (eds). Current Medicine Group, Philadelphia, PA, 2007.
25. Pavelka JC, **Karlan BY**: Vaginal cancer. In: *Gynecology for the Primary Care Physician*, 2nd Edition, Chapter 26. Stovall TG, Ling FW, Nikki BZ, Chuang AW, Tillmanns TT (eds). Current Medicine Group, Philadelphia, PA, 2007.
26. **Karlan BY**, Lang J: Cancer screening – Colorectal cancer. In: *5-Minute Ob/Gyn Consult*. Hilard PJ, Hillard PJ (eds). Lippincott, Williams and Wilkins: Philadelphia. PA, 2008.
27. **Karlan BY**, Lang J: Screening and well-woman care – ACOG guidelines. In: *5-Minute Ob/Gyn Consult*. Hilard PJ, Hillard PJ (eds). Lippincott, Williams and Wilkins: Philadelphia. PA, 2008.
28. Cass I, **Karlan BY**: Ovarian and Tubal Cancers In: Gibbs RS, Karlan BY, Haney A, Nygaard I (eds): *Danforth's 10th Edition Obstetrics and Gynecology*. Lippincott Williams and Wilkins, Philadelphia, PA, 2008.
29. Holschneider CH, **Karlan BY**: Cytoreductive Surgery: Principles and Rationale, Chapter 4 pp 61-90. In: *Surgery for Ovarian Cancer Principles and Practice*, 2nd Edition. Bristow RE, Karlan BY and Chi DS (eds). Taylor & Francis Publishers, United Kingdom, 2010.
30. Zivanovic O, Chi DS, **Karlan BY**: Advanced Cytoreductive Surgery Program Development: Building a Cytoreductive Team, Chapter 15, pp 291-299. In: *Surgery for Ovarian Cancer Principles and Practice*, 2nd Edition. Bristow RE, Karlan BY and Chi DS (eds). Taylor & Francis Publishers, United Kingdom, 2010.
31. Holschneider CH, Sehouli J, **Karlan BY**: Cytoreductive surgery: Principles and rationale, Chapter 6, pp 105-151. In: *Surgery for Ovarian Cancer: Principles and Practice, Third Edition*, Bristow RE, Karlan BY and Chi DS (eds). Taylor & Francis Publishers, United Kingdom, 2016.
32. Al-Niaimi AN, Rice LW, **Karlan BY**: Building a multidisciplinary surgical team to optimize patient outcomes, Chapter 19, pp423-429. In: *Surgery for Ovarian Cancer: Principles and Practice, Third Edition*, Bristow RE, Karlan BY and Chi DS (eds). Taylor & Francis Publishers, United Kingdom, 2016.

## F. Text Books

1. **Karlan BY**, Surrey ES (eds): *Gynecologic Emergencies*, In: Infertility and Reproductive Medicine Clinics of North America. W.B. Saunders Co., 1992.
2. **Karlan BY** (ed): *Familial Cancer Syndromes*, In: *Clinical Obstetrics and Gynecology*. Lippincott-Raven Publishers, 1998.
3. Scott J, Gibbs RS, **Karlan B**, Haney A (eds): *Danforth's 9<sup>th</sup> Edition Obstetrics and Gynecology*. Lippincott Williams and Wilkins, Philadelphia, PA. 2003.
4. Bristow RE, **Karlan BY** (eds): *Surgery for Ovarian Cancer: Principles and Practice*. Taylor and Francis Publishing, United Kingdom. 2006.
5. Gibbs RS, **Karlan BY**, Haney A, Nygaard I (eds): *Danforth's 10th Edition Obstetrics and Gynecology*. Lippincott Williams and Wilkins, Philadelphia, PA, 2008.

6. Bristow RE, **Karlan BY**, Chi D, (eds): *Surgery for Ovarian Cancer: Principles and Practice, 2<sup>nd</sup> Edition*. Taylor and Francis Publishing, United Kingdom, 2010.
7. **Karlan BY**, Bristow RE, Li AJ (eds): *Gynecologic Oncology: Clinical Practice and Surgical Atlas*. McGraw-Hill Publishers, New York, New York, 2012.
8. Bristow RE, **Karlan BY**, Chi D (eds): *Surgery for Ovarian Cancer: Principles and Practice, Third Edition*. Taylor and Francis Publishing, United Kingdom, 2016.

## **G. Letters to the Editor**

1. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, **Karlan B**, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: Localization of human *BRCA1* and its loss in high-grade, non-inherited breast carcinomas. *Nature Genetics* 21:236-240, 1999.
2. Karam AK, **Karlan BY**: Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer. *Gynecol Oncol*. 116(1):149-50, 2010.

## **H. Editorials**

1. **Karlan BY**: Where are we now and where are we going? *Gynecol Oncol* 59(3):315-317 1995. PMID: 8522246
2. **Karlan BY**: Defining cancer risks for *BRCA* germline mutation carriers: implications for surgical prophylaxis. *Gynecol Oncol* 92(2):519-520, 2004.
3. **Karlan BY**: Profiling the perpetrator. *J Clin Oncol* 22(23):4663-4664, 2004. PMID: 15505273
4. **Karlan BY**: The colon is a pelvic organ too: taking the Couric challenge. *Obstet Gynecol* 104(5 Pt 1):907-909, 2004. PMID: 15516375
5. **Karlan BY**: Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources: Committee on Government Reform United States House of Representatives. *Gynecol Oncol* 99(2):257-260, 2005. PMID: 16315346
6. **Karlan BY**: Evolution through intelligent design. *Gynecol Oncol*. 102(1):1-4, 2006. PMID: 16777526
7. **Karlan BY**, McIntosh M: The quest for ovarian cancer's Holy Grail: can CA125 still be the chalice of early detection? *J Clin Oncol* 25(11):1303-1304, 2007. PMID: 17416848
8. **Karlan BY**: Can lifestyle influence genetics? *Nature Clin Pract Oncol* 4(10):555, 2007. PMID: 17898806
9. **Karlan BY**: Dawn of a new era for *Gynecologic Oncology*. *Gynecol Oncol* 108:2, 2008.
10. **Karlan BY**: The devil is in the details. *Gynecol Oncol* 108:261, 2008.
11. **Karlan BY**: Improving efficiencies in translational science. *Gynecol Oncol* 108(3):461, 2008. PMID: 18294531

12. Walsh CS, **Karlan BY**: Lymphadenectomy's role in early endometrial cancer: prognostic or therapeutic? *J Natl Cancer Inst* 100(23):1660-1661, 2008. PMID: 19033560
13. Cass I, **Karlan BY**: Ovarian cancer symptoms speak out—but what are they really saying? *J Natl Cancer Inst* 102(4):211-212, 2010. PMID: 20110550
14. **Karlan BY**: Gynecologic Oncology Update 2010. *Gynecol Oncol* 118(3):209, 2010.
15. Chi DS, Bristow RE, Armstrong DK, **Karlan BY**: Is the easier way ever the better way? *J Clin Oncol*, 29(31):4073-4075; 2011. PMID: 21931018.
16. **Karlan BY**: Gynecologic Oncology: Update 2012. *Gynecologic Oncology*, 124(2):177; 2012.
17. Swisher EM, Taniguchi T, **Karlan BY**: Molecular scores to predict ovarian cancer outcomes: A worthy goal, but not ready for prime time. *J Natl Cancer Inst*, 104(9):642-645; 2012. PMID: 22505475
18. **Karlan BY**, Chief Editors of Journals Participating in the CI. The CROWN Initiative: Journal editors invite researchers to develop core outcomes in women's health. *Gynecol Oncol* 134(3):443-444; 2014. PMID: 25199578.
19. **Karlan BY**: Dawn of a new cover. *Gynecol Oncol* 137(1):1; April 2015.
20. **Karlan BY**: Gynecologic oncology 2017 update: New features and expanded scope. *Gynecol Oncol* 144(1):1-2; Jan 2017. PMID: 28012554
21. Chuang LT, Randall TC, **Karlan BY**. Efforts towards erasing borders in gynecologic cancer? *Gynecol Oncol Rep* 21:5-6; 2017. PMID: 28540361

### Abstracts – Since 2012

1. Cass I, Zakhour M, Walts A, Gross J, **Karlan B**: Occult cancers at risk-reducing salpingo-oophorectomies (RRSO) in *BRCA* mutation carriers. 43<sup>rd</sup> Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, March 2012.
2. Cass I, Saad C, Li A, Walsh C, Gross J, **Karlan B**: High prevalence of primary peritoneal serous carcinoma among Jewish *BRCA* mutation carriers may limit the efficacy of screening ultrasound for early detection. 43<sup>rd</sup> Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, March 2012.
3. Rimel BJ, Russ H, Walsh C, Gross J, Bresee C, Cook-Wiens G, **Karlan BY**: Shortened telomere length in ovarian cancer patients with *BRCA1/2* mutation. The Fourth International Symposium on Hereditary Breast and Ovarian Cancer, Montreal, Canada, April 2012.
4. Wenzel L, Osan K, Gross J, Kurz R, Hsieh S, Rimel BJ, Nelson EL, **Karlan BY**: Can psychosocial risk factors and biopsychological stress markers help determine which *BRCA* mutation carriers need counseling intervention? The Fourth International Symposium on Hereditary Breast and Ovarian Cancer, Montreal, Canada, April 2012.
5. **Karlan BY**, Lu J, Navale L, Rasmussen E, Sun Y-N, Vergote IB, Kuchimanchi M, Warner D, Weinreich DM: Exposure-response relationship of open-label (OL) AMG 386 monotherapy in patients (pts) with recurrent ovarian cancer. Annual ASCO Meeting, Chicago, IL, June 2012.
6. Diaz ES, Baquing MA, Li AJ, Walsh CS, Leuchter RS, **Karlan BY**, Cass I: Predictors of residual disease at hysterectomy following cervical conizations with positive margins. Annual Meeting of the Western Association of Gynecologic Oncologists and Felix Rutledge Society Meeting (Poster Presentation),



Huntington Beach, CA, June 2012.

7. Cohen JG, Zakhour M, Rimel BJ, Li A, Cass I, **Karlan B**, Walsh CS: Identification of gynecologic oncology patients that can be fast-tracked for early discharge. Western Association of Gynecologic Oncologists and Felix Rutledge Society Meeting (Poster Presentation), Huntington Beach, CA, June 2012.
8. Mahller Y, Walsh C, Cass I, Rimel B, **Karlan B**, Li A: Peri-operative ketorolac is associated with improved epithelial ovarian cancer survival. Western Association of Gynecologic Oncologists and Felix Rutledge Society Meeting (Poster Presentation), Huntington Beach, CA, June 2012.
9. Zakhour M, Li A, Walsh C, Cass I, **Karlan B**, Rimel B: Post-treatment surveillance of type II endometrial cancer survivors. Western Association of Gynecologic Oncologists and Felix Rutledge Society Meeting (Poster Presentation), Huntington Beach, CA, June 2012.
10. Diaz E, Liburd N, Chen I, **Karlan B**, Li A: Obesity-associated adipokines correlate with survival in epithelial ovarian cancers. Western Association of Gynecologic Oncologists and Felix Rutledge Society Meeting (Oral Presentation), Huntington Beach, CA, June 2012.
11. Beach JA, Cheon D-J, Berel D, **Karlan BY**, Orsulic S: Defining metabolic differences between breast cancer stem cells and differentiated cancer cells (Poster Presentation). Inaugural Graduate Student Symposium: Research in Translational Medicine, October, 2012.
12. Cheon D-J, Tong Y, Sim M-S, Cui X, Wiedemeyer R, Berel D, Tighiouart M, Lester J, **Karlan BY**, Orsulic S: Stromal gene signature as a predictor of clinical outcome and a therapeutic target in ovarian cancer. The Cancer Genome Atlas 2<sup>nd</sup> Annual Scientific Symposium: Enabling Cancer Research through TCGA (Poster Presentation), Crystal City, VA, November 2012.
13. Cheon D-J, Yunguang T, Sim M-S, Cui X, Wiedemeyer R, Berel D, Tighiouart M, Lester J, **Karlan BY**, Orsulic S: Stromal gene signature regulated by TCF $\beta$  signaling predicts poor clinical outcome in ovarian cancer (Poster Presentation). CSMC Research Day, Los Angeles, CA, January, 2013.
14. Aspuria P-J, Cheon D-J, Gozo M, Salumbides B, Vergnes L, Asara J, Reue K, **Karlan BY**, Orsulic S: HOBX13 inhibition of succinate dehydrogenase leads to epithelial-to-mesenchymal transition in mouse ovarian cancer cell lines (Poster Presentation). CSMC Research Day, Los Angeles, CA, January, 2013.
15. Beach JA, Aspuria P-J, Gozo MC, Cheon D-J, **Karlan BY**, Orsulic S: The role of sphingosine kinase-1 in ovarian cancer progression and the tumor microenvironment (Poster Presentation). CSMC Research Day, Los Angeles, CA, January, 2013.
16. Aspuria P-J, Cheon D-J, Gozo M, Salumbides B, Vergnes L, Asara J, Reue K, **Karlan BY**, Orsulic S: HOBX13 inhibition of succinate dehydrogenase leads to epithelial-to-mesenchymal transition in mouse ovarian cancer cell lines, Keystone Conference Tumor Metabolism (Poster Presentation), Keystone, CO, February 24 – March 01, 2013.
17. Singh K, Lester J, **Karlan BY**, Bresee C, Geva T, Gordon O: Impact of Family History on Choosing Risk-Reducing Surgery Among *BRCA* Mutation Carriers. IV Annual IMPPC Conference/1<sup>st</sup> ICO-DIBELL Hereditary Cancer Program Meeting, (Poster Presentation), Barcelona, Spain, March 2013.
18. Cass I, Walsh C, Lester J, Li A, **Karlan B**: Patterns of care for risk-reducing salpingo-oophorectomy (RRSO) for *BRCA* mutation carriers and subsequent surveillance. Society of Gynecologic Oncology 44<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Los Angeles, CA, March 2013.
19. Diaz ES, Agadjanian H, Nassanian H, Walts A, Miller C, Zajchowski D, Orsulic S, **Karlan B**, Walsh C: P13K pathway activation, thromboembolism and survival in ovarian clear cell carcinoma. Society of Gynecologic

Oncology 44<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Los Angeles, CA, March 2013.

20. Agadjanian H, Cheon D, Diaz E, Laury A, Miller C, **Karlan B**, Orsulic S, Walsh C: A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Annual Meeting of American Association of Cancer Research (Poster Presentation), Washington, DC, April 2013.
21. Jin Y, Han B, Wiedemeyer R, Orsulic S, Bose S, **Karlan BY**, Giuliano AE, Cui X: FOC1 is a critical mediator of EGFR function in basal-like breast cancer. Annual Meeting of American Association of Cancer Research (Poster Presentation), Washington, DC, April 2013.
22. Cheon D-J, Tong Y, Kim M-S, Cui X, Dror B, Tighiouart M, **Karlan BY**, Orsulic S: Stromal gene signature regulated by TGF $\beta$  signaling predicts poor clinical outcome in ovarian cancer, Annual Meeting of American Association of Cancer Research (Poster Presentation), Washington, DC, April 2013.
23. Aspuria P-J, Cheon D-J, Gozo M, Salumbides B, Vergnes L, Asara J, Reue K, **Karlan BY**, Orsulic S: HOBX13 inhibition of succinate dehydrogenase leads to epithelial-to-mesenchymal transition in mouse ovarian cancer cell lines, Annual Meeting of American Association of Cancer Research (Poster Presentation), Washington, DC, April 2013.
24. Taylor-Harding B, Agadjanian H, Orsulic S, Walsh C, **Karlan BY**, Wiedemeyer WR: Cell cycle requirements shape ovarian cancer progression, Annual Meeting of American Association of Cancer Research (Poster Presentation), Washington, DC, April 2013.
25. LaBrant L, Rimel B, Walsh C, Li A, **Karlan B**, Cass I: Too much, too late: Aggressive care in women with recurrent gynecologic malignancies and the timing of end-of-life discussions. Annual Meeting of the Western Association of Gynecologic Oncologists, Seattle, WA, June 2013.
26. Holzapfel M, Rimel B, Li A, Cass I, **Karlan B**, Walsh C: What drives the development of synchronous endometrioid endometrial and ovarian cancers? Annual Meeting of the Western Association of Gynecologic Oncologists (Poster Presentation), Seattle, WA, June 2013.
27. Cohen J, Tran A, Rimel B, Cass I, Walsh C, **Karlan B**, Li A: Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival. Annual Meeting of the Western Association of Gynecologic Oncologists (Poster Presentation), Seattle, WA, June 2013.
28. Tran A, Rimel B, Walsh C, Cass I, **Karlan B**, Li A: Obesity correlates with overall survival in women with recurrent epithelial ovarian cancer. Annual Meeting of the Western Association of Gynecologic Oncologists (Poster Presentation), Seattle, WA, June 2013.
29. Paik D, Amersi F, Gangi A, Dang C, **Karlan B**, Leuchter R, Li A, Walsh C, Rimel B, Cass I: Patterns of breast cancer surveillance and detection in women with serous ovarian/tubal or peritoneal carcinomas who have had *BRCA* mutation testing. Annual Meeting of the Western Association of Gynecologic Oncologists (Poster Presentation), Seattle, WA, June 2013.
30. Wang ET, Pisarska MD, Bresee C, Yii-Der MS, Chen I, Alexander C, **Karlan BY**: Risk of diminished ovarian reserve in *BRCA1/2* mutation carriers. 69<sup>th</sup> Annual Meeting of the American Society of Reproductive Medicine (Poster Presentation), Boston, MA, October 2013.
31. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, DelCampo JM, Ray-Coquard IR, Provencher DM, **Karlan BY**, Lhomme C, Richardson G, Rincon DG, Coleman RL, Herzog TJ, Marth C, Brize A, Navale L, Warner D, Oza AM: A phase 3, randomized, double-blind trial of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer: Trinova-1. 18<sup>th</sup> International Meeting of the European Society of Gynaecological Oncology, Liverpool, UK, October 19-22, 2013.

32. Cheon D-J, Bomalaski JS, Walts AE, **Karlan BY**, Orsulic S: Non-serous ovarian carcinomas express low levels of ASS1: Implications for arginine depletions therapy. Cedars-Sinai Medical Center 5<sup>th</sup> Annual Research Day (Poster Presentation), Los Angeles, CA, January 17, 2014.
33. Aspuria P-J, Lunt SY, Varembo L, Vargnes L, Reue K, Nielsen J, **Karlan BY**, Orsulic S: Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cedars-Sinai Medical Center 5<sup>th</sup> Annual Research Day, Los Angeles, CA (Poster Presentation), January 17, 2014.
34. Paik, D, Amersi F, Bresee C, Dang C, **Karlan B**, Li, A, Walsh C, Rimel BJ, Leuchter R, Cass I: Breast cancer following ovarian cancer in *BRCA* mutation carriers: What is the cost of surveillance? Cedars-Sinai Medical Center 5<sup>th</sup> Annual Research Day, Los Angeles, CA (Poster Presentation), January 17, 2014.
35. Beach JA, Aspuria P-J, Cheon J-J, Gozo MC, **Karlan BY**, Orsulic S: The role of sphingosine kinase-1 in ovarian cancer progression and the tumor microenvironment. Cedars-Sinai Medical Center 5<sup>th</sup> Annual Research Day, Los Angeles, CA (Poster Presentation), January 17, 2014.
36. Agadjanian H, Cheon D-J, Diaz E, Laury A, Miller C, **Karlan B**, Orsulic S, Walsh C: Mouse model of epithelial ovarian cancer with define oncogenic drivers. Cedars-Sinai Medical Center 5<sup>th</sup> Annual Research Day, Los Angeles (Poster Presentation), CA, January 17, 2014.
37. Babkina N, Orsulic Li X, Gordon O, **Karlan B**: Gene expression profile in ovarian stroma of *BRCA1* mutation carriers and age-matched *BRCA1/2* wild type controls. Cedars-Sinai Medical Center 5<sup>th</sup> Annual Research Day, Los Angeles, CA (Poster Presentation), January 17, 2014.
38. Cohen J, Wiedemeyer R, **Karlan B**, Walsh C: A KRAS hotspot mutation correlates with MLH1 methylation in endometrial carcinomas with microsatellite instability: A potential triage tool for Lynch Syndrome evaluation. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
39. Cohen J, Goodman M, **Karlan B**, Walsh C: Genomic characterization of grade 3 endometrial carcinoma. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
40. Cohen J, Goodman M, **Karlan B**, Walsh C: Lack of genomic predictors of recurrence in uterine carcinoma. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
41. Cohen J, Mehta S, Rimel BJ, Walsh C, Li A, **Karlan B**, Cass I: Risk factors for recurrent high grade vaginal intraepithelial neoplasia and progression to carcinoma. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
42. Rimel BJ, Lester J, Dang C, Sabacan L, Park D, **Karlan B**: A novel clinical trial recruitment strategy for women's cancers. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
43. Zakhour M, Labrant L, Rimel BJ, Walsh C, Li A, **Karlan B**, Cass I: Too much too late aggressive measures and the timing of end-of-life care discussions in women with gynecologic malignancies. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Featured Poster Presentation), Tampa, FL, March 22-26, 2014.
44. Paik D, Amersi F, Gangi A, Bresee C, Dang C, **Karlan B**, Li A, Walsh C, Rimel BJ, Leuchter R, Cass I: Breast cancer following ovarian cancer in *BRCA* mutation carriers: What is the cost of surveillance? Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March

22-26, 2014.

45. Paik D, Amersi F, Bresee C, Dang C, Gangi A, **Karlan B**, Li A, Walsh C, Rimel BJ, Leuchter R, Cass: Risk of breast cancer following ovarian cancer and the impact on overall survival. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
46. Tran A, Rimel BJ, Walsh C, Cass I, **Karlan B**, Li AJ: Impact of obesity on outcome of secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
47. Rimel B, Dang C, Lester J, Sabacan L, Park D, Daneshvar C, **Karlan B**: A novel online registry to improve clinical trial accrual. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Tampa, FL, March 22-26, 2014.
48. Herzog TJ, Richardson GE, Monk BJ, **Karlan B**, Marth C, Navale L, Warner DJ, Oza AM: Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer. Society of Gynecologic Oncology 45<sup>th</sup> Annual Meeting on Women's Cancer (Oral Presentation), Tampa, FL, March 22-26, 2014.
49. Zakhour M, **Karlan B**, Walts AE, Gross J, Rimel BJ, Walsh C, Li AJ, Cass I: Occult and subsequent gynecologic cancers following risk-reducing salpingo-oophorectomies (RRSO) in *BRCA* mutation carriers. Western Association of Gynecologic Oncologists Meeting (Oral Presentation), Truckee, CA, June 25-28, 2014.
50. Park SK, Axtell AE, Hakimian B, Li A, Leuchter R, **Karlan B**, Rimel BJ, Walsh C, Cass I: Morbidity of triplemodality therapy in the management of early stage cervical cancer. Western Association of Gynecologic Oncologists Meeting (Poster Presentation), Truckee, CA, June 25-28, 2014.
51. Li A, Cheon D, **Karlan B**, Orsulic S: The prognostic significance of ADAM metallopeptidase domain 12 in advanced stage serous ovarian cancer. Western Association of Gynecologic Oncologists Meeting (Oral Presentation), Truckee, CA, June 25-28, 2014.
52. Terry KL, Babic A, **Karlan BY**, Goodman MT, Lambrecht D, Heitz F, Matsuo K, McNeish I, Pejovic T, Kruger Kjaer S, Webb PM, Hogdall E, Goode EL, Dramer DW, for the Ovarian Cancer Association Consortium: Epidemiologic predictors of pre-treatment CA125 in women with ovarian cancer. Society of Gynecologic Oncology 46<sup>th</sup> Annual Meeting on Women's Cancer (Oral Presentation – DOD Ovarian Cancer Academy Session), Chicago, IL, March 28-31, 2015.
53. Park SK, Amneus MW, Axtell AE, Hakimian B, Li AJ, Leuchter RS, **Karlan BY**, Rimel BJ, Walsh C, Holschneider CH, Cass I: Morbidity of triple modality therapy in the management of early stage cervical cancer. Society of Gynecologic Oncology 46<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Chicago, IL, March 28-31, 2015.
54. Martin S, Walsh C, Rimel BJ, Cass I, **Karlan B**, Li A: Serum interleukin-6 is a biomarker of survival in women with advanced stage and optimally resected epithelial ovarian cancer. Society of Gynecologic Oncology 46<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Chicago, IL, March 28-31, 2015.
55. Jenkins Vogel T, Qu, Y, Suzuki E, Drapkin RI, Sareen D, Svendsen CN, Cui X, **Karlan BY**: Co-culture of human induced pluripotent stem cells (iPSCs) with human fallopian tube epithelium (FTE) induces *Pax8* and *CK7* expression: Initial steps in modeling fallopian tube epithelium to study serous carcinogenesis. Society of Gynecologic Oncology 46<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), Chicago, IL, March 28-31, 2015.
56. Jenkins Vogel T, Jeon C, **Karlan B**, Walsh C: Does digoxin improve ovarian cancer survival by inducing

immunogenic cell death? A SEER-Medicare database analysis. Society of Gynecologic Oncology 46th Annual Meeting on Women's Cancer (Poster Presentation), Chicago, IL, March 28-31, 2015.

57. Vogel TJ, Cohen J, Han B, Walts AE, Zhang X, **Karlan BY**, Cui X: The role of FOXC1 in clear cell ovarian carcinoma: Potential prognostic biomarker for aggressive disease? Western Association of Gynecologic Oncologists Meeting (Poster Presentation), Santa Rosa, CA, June 11-13, 2015.
58. Martin S, Walsh C, Rimel BJ, Cass I, **Karlan BY**, Li AJ: Serum interleukin-6 is a biomarker of survival in women with advanced stage and optimally resected epithelial ovarian cancer. Western Association of Gynecologic Oncologists Meeting (Poster Presentation), Santa Rosa, CA, June 11-13, 2015.
59. Prendergast EN, Green M, Zakhour M, Lester J, Li AJ, Walsh C, Rimel BJ, Leuchter RS, **Karlan BY**, Cass I: Bone density testing under utilized in *BRCA* population following risk-reducing salpingo-oophorectomy. Society of Gynecologic Oncology 47<sup>th</sup> Annual Meeting on Women's Cancer (Oral Presentation), San Diego, CA, March 19-22, 2016.
60. Liang MI, Prendergast EN, Rimel BJ, Walsh CS, Cass I, **Karlan BY**, Li AJ: Antibiotics and the commensal microbiota: Impact on survival in women with epithelial ovarian cancer. Society of Gynecologic Oncology 47<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), San Diego, CA, March 19-22, 2016.
61. Prendergast EN, Green M, Zakhour M, Lester J, Li AJ, Walsh C, Rimel BJ, Leuchter RS, **Karlan BY**, Cass I: Primary peritoneal carcinoma surveillance practices following risk-reducing salpingo-oophorectomy (RRSO) in *BRCA* mutation carriers. Society of Gynecologic Oncology 47<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), San Diego, CA, March 19-22, 2016.
62. Zakhour M, Saad C, Rimel BJ, Walsh C, Li A, **Karlan B**, Leuchter R, Cass I: Characteristics of primary peritoneal serous carcinoma (PPSC) in the U.S. Population enriched for Jewish ancestry. Society of Gynecologic Oncology 47<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), San Diego, CA, March 19-22, 2016.
63. Zakhour M, Laury A, Lester J, Rimel BJ, Walsh C, Li A, **Karlan B**, Leuchter R, Cass I: Serous tubal intraepithelial carcinoma (STIC) lesions are common in primary peritoneal serous carcinomas. Society of Gynecologic Oncology 47<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), San Diego, CA, March 19-22, 2016.
64. Prendergast EN, Liang MI, Staples JN, Lester J, Li AJ, Walsh C, Rimel BJ, Leuchter RS, **Karlan BY**, Cass I: Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer. Society of Gynecologic Oncology 47<sup>th</sup> Annual Meeting on Women's Cancer (Poster Presentation), San Diego, CA, March 19-22, 2016.
65. Liang M, Prendergast E, Rimel B, Leuchter R, Walsh C, Cass I, **Karlan B**, Li A: Antibiotic use negatively influences survival in epithelial ovarian cancer: A case for studying the micro biome (Oral Presentation). Annual meeting of the Western Association of Gynecologic Oncologists, Sedona, AZ, June 08-11, 2016
66. Liang M, Holzapfel M, Chang H, Lester J, Li A, Cass I, Rimel B, **Karlan B**, Leuchter R, Walsh: Glasgow prognostic score associated with lower rates of R0 cytoreduction in women with stage III serous ovarian cancer (Poster Presentation). Annual meeting of the Western Association of Gynecologic Oncologists, Sedona, AZ, June 08-11, 2016.
67. Hodeib M, Cass I, Rimel BJ, Li AJ, **Karlan BY**, Walsh C: PD-1 and PD-11 staining patterns in cervical squamous cell carcinoma (Poster Presentation). Annual meeting of the Western Association of Gynecologic Oncologists, Sedona, AZ, June 08-11, 2016
68. Hodeib M, Walsh C, **Karlan B**, Aspuria PJ: Activated stromal mast cells in high grade serous ovarian cancers

(HGSC) are associated with poor overall survival (Oral Presentation). Annual meeting of the Western Association of Gynecologic Oncologists, Sedona, AZ, June 08-11, 2016

69. Liu, AY, Lester J, Laury A, Cass I, Rimel BJ, Li AJ, **Karlan BY**, Walsh CS: PD-1 and PD-L1 expression in advanced endometrial adenocarcinoma (Poster Presentation). Annual meeting of the Western Association of Gynecologic Oncologists, Sedona, AZ, June 08-11, 2016
70. Hodeib M, Ogradzinski M, Vergnes L, Reuek K, Lunt S, Walsh C, **Karlan BY**, Aspuria PJ: Metformin and phenformin inhibit cell proliferation and alter metabolism in high grade serous ovarian cancer. (Poster Presentation). Society of Gynecologic Oncology 48<sup>th</sup> Annual Meeting on Women's Cancer, National Harbor, MD, March 12-15, 2017.
71. Hodeib M, Walsh C, Knudsen B, **Karlan BY**, Aspuria PJ: Mast cells are a newly identified immune component of the mesenchymal subtype in high grade serous ovarian cancer (HGSC). (Poster Presentation). Society of Gynecologic Oncology 48<sup>th</sup> Annual Meeting on Women's Cancer, National Harbor, MD, March 12-15, 2017.
72. Wield A, **Karlan BY**, Cass I, Walsh CS, Rimel BJ, Li A: Aspirin use and ovarian clear cell carcinoma. (Poster Presentation). Western Association of Gynecologic Oncologists, Rancho Mirage, CA, June 14-16, 2017.
73. Hodeib M, McMillen K, Zakhour M, Rimel BJ, Li A, Walsh C, **Karlan BY**, Cass I: Risk of uterine cancer in women with deleterious *BRCA* mutations who undergo risk reducing salpingo-oophorectomy (RRSO). (Poster Presentation). Western Association of Gynecologic Oncologists, Rancho Mirage, CA, June 14-16, 2017.
74. Dorayappan K, Zingarelli R, Hisey C, Smith B, Wanner R, Saini U, Hansford D, Wallbillich J, She J, Lester J, **Karlan BY**, Suarez A, Cohn D, Karuppaiyah S: Evaluating exosome proteins as biomarkers for the early detection of high-grade serous ovarian cancer. (Poster Presentation). Society of Gynecologic Oncology 49<sup>th</sup> Annual Meeting on Women's Cancer, New Orleans, LA, March 23-27, 2018.
75. Chang H, Rimel BJ, Li AJ, Cass I, **Karlan BY**, Walsh C: Outcomes with ultrasound guided trans versus abdominal plane (TAP) block after open gynecologic surgery. (Poster Presentation). Society of Gynecologic Oncology 49<sup>th</sup> Annual Meeting on Women's Cancer, New Orleans, LA, March 23-27, 2018.
76. Radke MR, Swisher EM, Harrell MI, Agnew KJ, Garcia RL, Bernards SS, **Karlan BY**, Lester J, Norquist BM: Somatic reversion mutations in hereditary ovarian carcinomas predict platinum sensitivity. (Poster Presentation). Society of Gynecologic Oncology 49<sup>th</sup> Annual Meeting on Women's Cancer, New Orleans, LA, March 23-27, 2018.